Identification

Name
Ketamine
Accession Number
DB01221  (APRD00493)
Type
Small Molecule
Groups
Approved, Vet approved
Description

Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[6] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[14]

Structure
Thumb
Synonyms
  • (+-)-Ketamine
  • (±)-ketamine
  • 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
  • 2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
  • 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
  • DL-ketamine
  • Ketamina
  • Kétamine
  • Ketaminum
  • NMDA
  • Special K
External IDs
100477-72-3 / NSC-70151
Product Ingredients
IngredientUNIICASInChI Key
Ketamine hydrochlorideO18YUO0I831867-66-9VCMGMSHEPQENPE-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
KetalarSolution10 mgIntramuscular; IntravenousErfa Canada 2012 Inc1972-12-31Not applicableCanada
KetalarSolution50 mgIntramuscular; IntravenousErfa Canada 2012 Inc1972-12-31Not applicableCanada
KetalarInjection10 mg/1mLIntramuscular; IntravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
KetalarInjection100 mg/1mLIntramuscular; IntravenousMonarch Pharmaceuticals, Inc.1970-02-192007-10-01Us
KetalarInjection100 mg/1mLIntramuscular; IntravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
KetalarInjection50 mg/1mLIntramuscular; IntravenousMonarch Pharmaceuticals, Inc.1970-02-192007-10-01Us
KetalarInjection50 mg/1mLIntramuscular; IntravenousPar Pharmaceutical, Inc.2007-10-01Not applicableUs
KetalarInjection10 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines2012-10-17Not applicableUs
KetalarInjection10 mg/1mLIntramuscular; IntravenousMonarch Pharmaceuticals, Inc.1970-02-192007-10-01Us
Ketamine Hydrochloride Injection SdzSolution50 mgIntramuscular; IntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ketamine HydrochlorideInjection10 mg/1mLIntramuscular; IntravenousPar Pharmaceutical2012-06-012018-05-06Us
Ketamine HydrochlorideInjection, solution100 mg/1mLIntramuscular; IntravenousMylan Institutional LLC2013-06-04Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate50 mg/1mLIntramuscular; IntravenousPhysicians Total Care, Inc.2002-03-12Not applicableUs
Ketamine HydrochlorideInjection, solution100 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines2018-02-28Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate100 mg/1mLIntramuscular; IntravenousHospira, Inc.2004-11-30Not applicableUs
Ketamine HydrochlorideInjection, solution, concentrate50 mg/1mLIntramuscular; IntravenousGeneral Injectables & Vaccines2012-10-11Not applicableUs
Ketamine HydrochlorideInjection100 mg/1mLIntramuscular; IntravenousPar Pharmaceutical2012-06-012018-05-12Us
Ketamine HydrochlorideInjection50 mg/1mLIntramuscular; IntravenousBedford Pharmaceuticals1996-07-012013-03-31Us
Ketamine HydrochlorideInjection, solution50 mg/1mLIntramuscular; IntravenousMylan Institutional LLC2013-06-04Not applicableUs
Ketamine HydrochlorideInjection100 mg/1mLIntramuscular; IntravenousRemedy Repack2017-05-302017-05-30Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Topical Nerve PainKetamine (0.1 g/100mL) + Diazepam (0.1 g/100mL) + Diclofenac sodium (0.1 g/100mL) + Gabapentin (0.1 g/100mL)CreamTopicalDr Marc's Manufacturing And Sales2016-02-23Not applicableUs
International/Other Brands
Ketaject (Bristol-Myers Squibb) / Ketanest (Parke Davis)
Categories
UNII
690G0D6V8H
CAS number
6740-88-1
Weight
Average: 237.725
Monoisotopic: 237.092041846
Chemical Formula
C13H16ClNO
InChI Key
YQEZLKZALYSWHR-UHFFFAOYSA-N
InChI
InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3
IUPAC Name
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
SMILES
CNC1(CCCCC1=O)C1=CC=CC=C1Cl

Pharmacology

Indication

Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[15]

Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[7] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[16, 8]

Associated Therapies
Pharmacodynamics

Ketamine is a rapid-acting general anesthetic producing an anesthetic state characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression. The anesthetic state produced by Ketamine has been termed as "dissociative anesthesia" in that it appears to selectively interrupt association pathways of the brain before producing somesthetic sensory blockade. It may selectively depress the thalamoneocortical system before significantly obtunding the more ancient cerebral centers and pathways (reticular-activating and limbic systems).[2]

Ketamine enhances descending inhibiting serotoninergic pathways and can exert antidepressive effects. These effects are seen in concentrations ten times lower than the needed concentration for anesthetic proposes. The effect of ketamine can be described as analgesic by the prevention of central sensitization in dorsal horn neurons as well as by the inhibition on the synthesis of nitric oxide. Ketamine can present cardiovascular changes and bronchodilatation.[9]

Mechanism of action

Ketamine interacts with N-methyl-D-aspartate (NMDA) receptors, opioid receptors, monoaminergic receptors, muscarinic receptors and voltage sensitive Ca ion channels. Unlike other general anaesthetic agents, ketamine does not interact with GABA receptors.[5]

TargetActionsOrganism
AGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
USubstance-P receptor
antagonist
Human
UD(2) dopamine receptor
agonist
partial agonist
Human
UDelta-type opioid receptor
binder
Human
USodium-dependent noradrenaline transporter
inhibitor
Human
UKappa-type opioid receptor
agonist
Human
UMu-type opioid receptor
binder
Human
UMuscarinic acetylcholine receptor
binder
Human
U5-hydroxytryptamine receptor 2
antagonist
Human
U5-hydroxytryptamine receptor 1
antagonist
Human
A5-hydroxytryptamine receptor 3A
potentiator
Human
AAlpha-7 nicotinic cholinergic receptor subunit
antagonist
Human
ACholinesterase
inhibitor
Human
ANitric oxide synthase, brain
inhibitor
Human
Absorption

Ketamine absorption is very rapid and the bioavailability is around 93%. After the first pass metabolism, only 17% of the administered dose is absorbed.[10] It distributes very rapidly and presents a distribution half-life of 1.95 min.[12] The Cmax levels at peak reach 0.75 mcg/ml in plasma and 0.2 mcg/ml in cerebrospinal fluid.[15]

Volume of distribution

The apparent volume of distribution of the central compartment and at steady-state are 371.3 ml/kg and 4060.3 ml/kg, respectively.[13]

Protein binding

The plasma protein binding of ketamine accounts for 53.5% of the administered dose.[12]

Metabolism

Ketamine presents a mainly hepatic metabolism and its major metabolite is norketamine. The biotransformation of ketamine corresponds to N-dealkylation, hydroxylation of the cyclohexone ring, conjugation to glucuronic acid and dehydration of the hydroxylated metabolites for the formation of cyclohexene derivatives.[10]

Route of elimination

Pharmacokinetic studies have resulted in the recovery of 85-95% of the administered dose in urine mainly in the form of metabolites. Some other routes of elimination of ketamine are bile and feces. When administered intravenously the resultant recovery is distributed by 91% of the administered dose in urine and 3% in feces.[15]

Half life

The reported half-life in preclinical studies for ketamine is 186 min.[10]

Clearance

The clearance rate of ketamine is high and of around 95 L/h/70kg.[11]

Toxicity

Preclinical studies related to the blocking of NMDA receptors have shown an increase in apoptosis in the developing brain which results in cognitive deficits when used for longer than 3 hours. Toxicity studies regarding carcinogenesis have not been performed. Regarding mutagenesis and fertility, ketamine showed to be clastogenic and to not have effects on fertility.[Label]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Ketamine is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Ketamine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbacavirAbacavir may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AcarboseAcarbose may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AceclofenacAceclofenac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Experimental, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aceprometazine.Approved
AcetaminophenAcetaminophen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
AcetarsolKetamine may decrease the excretion rate of Acetarsol which could result in a higher serum level.Approved, Withdrawn
AcetazolamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Ketamine is combined with Acetylglycinamide chloral hydrate.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
AclidiniumKetamine may decrease the excretion rate of Aclidinium which could result in a higher serum level.Approved
AcrivastineKetamine may decrease the excretion rate of Acrivastine which could result in a higher serum level.Approved
AcyclovirAcyclovir may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
AdefovirAdefovir may decrease the excretion rate of Ketamine which could result in a higher serum level.Investigational
Adefovir DipivoxilAdefovir Dipivoxil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AdinazolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ketamine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ketamine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ketamine is combined with Alaproclate.Experimental
Albutrepenonacog alfaKetamine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.Approved
AlcaftadineKetamine may decrease the excretion rate of Alcaftadine which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
AlcuroniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Alcuronium.Experimental
AldesleukinAldesleukin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ketamine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Allopregnanolone.Investigational
AllylestrenolKetamine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.Approved
AlmasilateKetamine may decrease the excretion rate of Almasilate which could result in a higher serum level.Approved, Experimental
AlminoprofenAlminoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Almotriptan.Approved, Investigational
AlogliptinKetamine may decrease the excretion rate of Alogliptin which could result in a higher serum level.Approved
AlosetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ketamine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ketamine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketamine.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Ketamine is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Ketamine is combined with Alverine.Approved, Investigational
AmantadineAmantadine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
AmikacinThe risk or severity of adverse effects can be increased when Ketamine is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideAmiloride may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.Approved
AmineptineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amineptine.Illicit, Withdrawn
AminophenazoneAminophenazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
AmiodaroneThe metabolism of Ketamine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Ketamine is combined with Amitriptylinoxide.Approved, Investigational
AmlodipineAmlodipine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Ammonium chlorideKetamine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.Approved, Investigational, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amoxapine.Approved
AmoxicillinAmoxicillin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Ketamine is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amphetamine.Approved, Illicit, Investigational
Amphotericin BAmphotericin B may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AmpicillinAmpicillin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
AmprenavirThe metabolism of Ketamine can be decreased when combined with Amprenavir.Approved, Investigational
AmrinoneKetamine may decrease the excretion rate of Amrinone which could result in a higher serum level.Approved
AncestimKetamine may decrease the excretion rate of Ancestim which could result in a higher serum level.Approved, Investigational, Withdrawn
AniracetamThe risk or severity of adverse effects can be increased when Ketamine is combined with Aniracetam.Experimental
Antihemophilic Factor (Recombinant), PEGylatedKetamine may decrease the excretion rate of Antihemophilic Factor (Recombinant), PEGylated which could result in a higher serum level.Approved, Investigational
AntipyrineAntipyrine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Antithrombin III humanKetamine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.Approved
AntrafenineAntrafenine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
ApalutamideThe serum concentration of Ketamine can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Ketamine is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Apramycin.Experimental, Vet Approved
ApremilastKetamine may decrease the excretion rate of Apremilast which could result in a higher serum level.Approved, Investigational
AprepitantThe serum concentration of Ketamine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Ketamine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Ketamine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Ketamine is combined with Arbekacin.Approved, Investigational
ArformoterolKetamine may decrease the excretion rate of Arformoterol which could result in a higher serum level.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole lauroxil.Approved, Investigational
ArotinololKetamine may decrease the excretion rate of Arotinolol which could result in a higher serum level.Investigational
Arsenic trioxideArsenic trioxide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Asenapine.Approved
AtazanavirThe metabolism of Ketamine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Ketamine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Ketamine is combined with Atracurium besylate.Approved
AuranofinAuranofin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AurothioglucoseKetamine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.Approved, Withdrawn
AzacitidineAzacitidine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Azaperone.Investigational, Vet Approved
AzapropazoneAzapropazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
AzathioprineKetamine may decrease the excretion rate of Azathioprine which could result in a higher serum level.Approved
AZD-3043The risk or severity of adverse effects can be increased when Ketamine is combined with AZD-3043.Investigational
Azelaic AcidAzelaic Acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
AzelastineKetamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AztreonamAztreonam may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
BacitracinBacitracin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
BaclofenThe risk or severity of adverse effects can be increased when Ketamine is combined with Baclofen.Approved
BalsalazideBalsalazide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
BarbexacloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Barbital.Illicit
BaricitinibKetamine may decrease the excretion rate of Baricitinib which could result in a higher serum level.Approved, Investigational
BeclamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Ketamine is combined with Benactyzine.Withdrawn
BendazacBendazac may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
BenmoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Benmoxin.Withdrawn
BenorilateBenorilate may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Ketamine is combined with Benperidol.Approved, Investigational
BenserazideKetamine may decrease the excretion rate of Benserazide which could result in a higher serum level.Approved, Investigational
BenznidazoleKetamine may decrease the excretion rate of Benznidazole which could result in a higher serum level.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Benzphetamine.Approved, Illicit
BenzydamineBenzydamine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ketamine is combined with Benzyl alcohol.Approved
BepotastineKetamine may decrease the excretion rate of Bepotastine which could result in a higher serum level.Approved
BicisateKetamine may decrease the excretion rate of Bicisate which could result in a higher serum level.Approved, Investigational
BifemelaneThe risk or severity of adverse effects can be increased when Ketamine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Ketamine is combined with Bifeprunox.Investigational
BimatoprostBimatoprost may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Bismuth subgallateKetamine may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.Approved
BisoprololBisoprolol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
BisoxatinKetamine may decrease the excretion rate of Bisoxatin which could result in a higher serum level.Approved
BL-1020The risk or severity of adverse effects can be increased when Ketamine is combined with BL-1020.Investigational
BleomycinBleomycin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Ketamine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Ketamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ketamine can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Ketamine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Ketamine is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
BrincidofovirBrincidofovir may decrease the excretion rate of Ketamine which could result in a higher serum level.Investigational
BrivaracetamThe risk or severity of adverse effects can be increased when Ketamine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromazepam.Approved, Illicit, Investigational
BromfenacBromfenac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
BromisovalThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ketamine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Brompheniramine.Approved
BronopolKetamine may decrease the excretion rate of Bronopol which could result in a higher serum level.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Brotizolam.Approved, Investigational, Withdrawn
BudesonideKetamine may decrease the excretion rate of Budesonide which could result in a higher serum level.Approved
BufexamacBufexamac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Experimental
BufotenineThe risk or severity of adverse effects can be increased when Ketamine is combined with Bufotenine.Experimental, Illicit
BumadizoneBumadizone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
BumetanideBumetanide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
BuprenorphineKetamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Ketamine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ketamine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketamine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Butalbital.Approved, Illicit
ButambenKetamine may decrease the excretion rate of Butamben which could result in a higher serum level.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Ketamine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketamine.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cabergoline.Approved
CalcitriolThe metabolism of Ketamine can be increased when combined with Calcitriol.Approved, Nutraceutical
CamazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Camazepam.Approved, Illicit
CanagliflozinKetamine may decrease the excretion rate of Canagliflozin which could result in a higher serum level.Approved
CannabidiolThe risk or severity of adverse effects can be increased when Ketamine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Ketamine is combined with Cannabidivarin.Investigational
CapecitabineCapecitabine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Ketamine is combined with Captodiame.Approved, Investigational
CarbamazepineThe metabolism of Ketamine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Carbinoxamine.Approved
CarboplatinCarboplatin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CarbromalThe risk or severity of adverse effects can be increased when Ketamine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Ketamine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Ketamine is combined with Carisoprodol.Approved
CarmustineCarmustine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Caroxazone.Withdrawn
CarprofenCarprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Cathinone.Illicit
CefacetrileCefacetrile may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefaclorCefaclor may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefadroxilCefadroxil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CefalotinCefalotin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
CefamandoleCefamandole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CefapirinCefapirin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
CefatrizineCefatrizine may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CefazedoneCefazedone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CefazolinCefazolin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefbuperazoneCefbuperazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CefcapeneCefcapene may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CefditorenCefditoren may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CefepimeCefepime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CefetametCefetamet may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CefmenoximeCefmenoxime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefmetazoleCefmetazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CefminoxCefminox may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefodizimeCefodizime may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CefonicidCefonicid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CefoperazoneCefoperazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CeforanideCeforanide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefotaximeCefotaxime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefotetanCefotetan may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefotiamCefotiam may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CefoxitinCefoxitin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefozopranCefozopran may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CefpiramideCefpiramide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefpiromeCefpirome may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefpodoximeCefpodoxime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
CefprozilCefprozil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefradineCefradine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefroxadineCefroxadine may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
CefsulodinCefsulodin may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
Ceftaroline fosamilCeftaroline fosamil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CeftazidimeCeftazidime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CeftezoleCeftezole may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CeftibutenCeftibuten may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CeftizoximeCeftizoxime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CeftobiproleCeftobiprole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CeftolozaneKetamine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.Approved, Investigational
CeftriaxoneCeftriaxone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CefuroximeCefuroxime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CelecoxibCelecoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CephalexinCephalexin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
CephaloglycinCephaloglycin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CephaloridineCephaloridine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
Cephalothin GroupCephalothin Group may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
CeritinibThe serum concentration of Ketamine can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cetirizine.Approved
Cetyl alcoholKetamine may decrease the excretion rate of Cetyl alcohol which could result in a higher serum level.Approved
CevimelineCevimeline may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ketamine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketamine.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chloroquine.Approved, Investigational, Vet Approved
ChloroxylenolKetamine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenamine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorphenesin.Approved, Experimental
ChlorproethazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ketamine.Approved, Investigational, Vet Approved
ChlorpropamideChlorpropamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Ketamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline C 11Ketamine may decrease the excretion rate of Choline C 11 which could result in a higher serum level.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Choline salicylateKetamine may decrease the excretion rate of Choline salicylate which could result in a higher serum level.Approved, Nutraceutical
Chondroitin sulfateKetamine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.Approved, Investigational, Nutraceutical
Chromic chlorideKetamine may decrease the excretion rate of Chromic chloride which could result in a higher serum level.Approved
Chromic citrateKetamine may decrease the excretion rate of Chromic citrate which could result in a higher serum level.Experimental
Chromic nitrateKetamine may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.Approved
ChromiumKetamine may decrease the excretion rate of Chromium which could result in a higher serum level.Approved
Chromium gluconateKetamine may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.Approved
Chromium nicotinateKetamine may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.Experimental
Chromous sulfateKetamine may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.Approved
CidofovirCidofovir may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CilansetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Cilansetron.Investigational
CilostazolCilostazol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CimetidineCimetidine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CimicoxibCimicoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Cinitapride.Approved, Investigational
CinnamaldehydeKetamine may decrease the excretion rate of Cinnamaldehyde which could result in a higher serum level.Approved, Experimental
Cinnamyl alcoholKetamine may decrease the excretion rate of Cinnamyl alcohol which could result in a higher serum level.Approved, Experimental
CinolazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Cinolazepam.Approved
CiprofloxacinCiprofloxacin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
CisaprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Ketamine is combined with Cisatracurium.Approved
CisplatinCisplatin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
CitalopramThe risk or severity of adverse effects can be increased when Ketamine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Ketamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clemastine.Approved, Investigational
ClevidipineKetamine may decrease the excretion rate of Clevidipine which could result in a higher serum level.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Ketamine is combined with Clobazam.Approved, Illicit
Clobetasol propionateThe metabolism of Ketamine can be increased when combined with Clobetasol propionate.Approved
ClobetasoneKetamine may decrease the excretion rate of Clobetasone which could result in a higher serum level.Approved
ClofarabineClofarabine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clomipramine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clonidine.Approved
ClonixinClonixin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ketamine is combined with Clopenthixol.Experimental
ClopidogrelThe serum concentration of Ketamine can be increased when it is combined with Clopidogrel.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketamine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Ketamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
Clove oilKetamine may decrease the excretion rate of Clove oil which could result in a higher serum level.Approved, Nutraceutical
CloxazolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketamine.Approved
CobicistatThe metabolism of Ketamine can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketamine.Approved, Illicit
ColchicineKetamine may decrease the excretion rate of Colchicine which could result in a higher serum level.Approved
ColistimethateThe risk or severity of adverse effects can be increased when Ketamine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Ketamine is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ketamine.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Corifollitropin alfaKetamine may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.Approved, Investigational
CresolKetamine may decrease the excretion rate of Cresol which could result in a higher serum level.Approved
CrisaboroleThe serum concentration of Ketamine can be increased when it is combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Ketamine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Ketamine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyamemazine.Approved
CyanocobalaminCyanocobalamin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Nutraceutical
CyclizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Cyproheptadine.Approved
Dabigatran etexilateKetamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.Approved
DabrafenibThe serum concentration of Ketamine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineKetamine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.Approved, Investigational
DalfampridineKetamine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.Approved
DanazolThe metabolism of Ketamine can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ketamine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dapoxetine.Investigational
DaptomycinDaptomycin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
DarunavirThe metabolism of Ketamine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ketamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Ketamine is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Ketamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeferiproneKetamine may decrease the excretion rate of Deferiprone which could result in a higher serum level.Approved
DelafloxacinKetamine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.Approved, Investigational
DelavirdineThe metabolism of Ketamine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Ketamine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketamine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desloratadine.Approved, Investigational
DesmopressinDesmopressin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ketamine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Detomidine.Vet Approved
DeutetrabenazineKetamine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.Approved, Investigational
DexamethasoneThe serum concentration of Ketamine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexbrompheniramine.Approved
DexibuprofenDexibuprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
DexketoprofenDexketoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Ketamine is combined with Dexmethylphenidate.Approved, Investigational
DexpanthenolKetamine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.Approved
DexrazoxaneDexrazoxane may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
DextofisopamThe risk or severity of adverse effects can be increased when Ketamine is combined with Dextofisopam.Investigational
DextranKetamine may decrease the excretion rate of Dextran which could result in a higher serum level.Approved, Investigational, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Ketamine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ketamine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ketamine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dezocine.Approved, Investigational
DiatrizoateDiatrizoate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketamine.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Ketamine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Ketamine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Dichloralphenazone.Approved, Illicit
Dichlorobenzyl alcoholKetamine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.Approved
DiclofenacDiclofenac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
DicyclomineDicyclomine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
DidanosineDidanosine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
DienogestKetamine may decrease the excretion rate of Dienogest which could result in a higher serum level.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ketamine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Difenoxin.Approved, Illicit
DifenpiramideDifenpiramide may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
DifluocortoloneKetamine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.Approved, Investigational, Withdrawn
DigoxinKetamine may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Ketamine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimenhydrinate.Approved
DimercaprolKetamine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimetacrine.Approved, Withdrawn
Dimethyl sulfoxideKetamine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.Approved, Vet Approved
DimethyltryptamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketamine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketamine.Approved, Illicit
DisopyramideDisopyramide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dixyrazine.Experimental
DL-MethylephedrineKetamine may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.Approved
DobutamineDobutamine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
DofetilideThe metabolism of Dofetilide can be decreased when combined with Ketamine.Approved, Investigational
DolasetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Ketamine is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Ketamine is combined with Donepezil.Approved
DopamineDopamine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
DoramectinThe risk or severity of adverse effects can be increased when Ketamine is combined with Doramectin.Vet Approved
DoripenemKetamine may decrease the excretion rate of Doripenem which could result in a higher serum level.Approved, Investigational
DorzolamideDorzolamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
DosulepinThe risk or severity of adverse effects can be increased when Ketamine is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Ketamine is combined with Doxepin.Approved, Investigational
DoxycyclineThe metabolism of Ketamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ketamine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Illicit
DronedaroneThe metabolism of Ketamine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ketamine is combined with Drotebanol.Experimental, Illicit
DroxicamDroxicam may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
DroxidopaKetamine may decrease the excretion rate of Droxidopa which could result in a higher serum level.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dyclonine.Approved
DyphyllineDyphylline may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ketamine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Edivoxetine.Investigational
EdoxabanKetamine may decrease the excretion rate of Edoxaban which could result in a higher serum level.Approved
EdrophoniumEdrophonium may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
EfavirenzThe metabolism of Ketamine can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Emepronium.Experimental
EmpagliflozinKetamine may decrease the excretion rate of Empagliflozin which could result in a higher serum level.Approved
EmylcamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Emylcamate.Experimental
EnalaprilatKetamine may decrease the excretion rate of Enalaprilat which could result in a higher serum level.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Ketamine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ketamine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Ketamine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Ketamine is combined with Epinastine.Approved, Investigational
EpirizoleEpirizole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
EplerenoneEplerenone may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Eplivanserin.Investigational
EpoprostenolKetamine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.Approved
ErgocalciferolThe metabolism of Ketamine can be decreased when combined with Ergocalciferol.Approved, Nutraceutical
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ketamine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ergotamine.Approved
ErtapenemErtapenem may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
ErythromycinThe metabolism of Ketamine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ketamine is combined with Escitalopram.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when Ketamine is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Esmirtazapine.Investigational
EsomeprazoleEsomeprazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketamine.Approved, Illicit
EstradiolEstradiol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol acetateKetamine may decrease the excretion rate of Estradiol acetate which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol cypionateKetamine may decrease the excretion rate of Estradiol cypionate which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol dienanthateKetamine may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level.Approved, Investigational, Vet Approved
Estradiol valerateKetamine may decrease the excretion rate of Estradiol valerate which could result in a higher serum level.Approved, Investigational, Vet Approved
Estrone sulfateKetamine may decrease the excretion rate of Estrone sulfate which could result in a higher serum level.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketamine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Ketamine is combined with Etacrynic acid.Approved, Investigational
EtafedrineKetamine may decrease the excretion rate of Etafedrine which could result in a higher serum level.Approved
EthadioneThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethadione.Experimental
EthambutolEthambutol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
EthanolKetamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthenzamideEthenzamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Ketamine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Etizolam.Approved
EtodolacEtodolac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Ketamine is combined with Etomidate.Approved
EtonogestrelEtonogestrel may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Etoperidone.Withdrawn
EtoposideThe metabolism of Ketamine can be increased when combined with Etoposide.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Ketamine can be decreased when it is combined with Etravirine.Approved
Eucalyptus oilKetamine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.Approved
Evening primrose oilKetamine may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.Investigational, Nutraceutical
EzogabineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Ketamine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Felbamate.Approved
FelbinacFelbinac may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenofibrateFenofibrate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Fenofibric acidKetamine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.Approved
FenoldopamFenoldopam may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FenproporexKetamine may decrease the excretion rate of Fenproporex which could result in a higher serum level.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ketamine.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Ketamine is combined with Fenyramidol.Experimental
FeprazoneFeprazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
FesoterodineKetamine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fexofenadine.Approved, Investigational
FirocoxibFirocoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental, Vet Approved
FlavoxateFlavoxate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Flibanserin.Approved, Investigational
FloctafenineFloctafenine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
FlomoxefFlomoxef may decrease the excretion rate of Ketamine which could result in a higher serum level.Investigational
Florbetaben (18F)Ketamine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.Approved
Florbetapir (18F)Ketamine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.Approved, Investigational
FloxuridineFloxuridine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ketamine can be decreased when combined with Fluconazole.Approved, Investigational
Fludeoxyglucose F-18Ketamine may decrease the excretion rate of Fludeoxyglucose F-18 which could result in a higher serum level.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Fludiazepam.Approved, Illicit
FlumazenilFlumazenil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunarizine.Approved
FlunisolideThe metabolism of Ketamine can be increased when combined with Flunisolide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Flunitrazepam.Approved, Illicit
FlunixinFlunixin may decrease the excretion rate of Ketamine which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
Fluocinolone acetonideThe metabolism of Ketamine can be increased when combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ketamine.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketamine.Approved
FlupirtineKetamine may decrease the excretion rate of Flupirtine which could result in a higher serum level.Approved, Investigational
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ketamine.Approved, Illicit, Investigational
FlurbiprofenFlurbiprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluspirilene.Approved, Investigational
FlutamideFlutamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Ketamine can be increased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Fluvoxamine.Approved, Investigational
Folic AcidFolic Acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Nutraceutical, Vet Approved
FomepizoleFomepizole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
FondaparinuxFondaparinux may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
FormestaneKetamine may decrease the excretion rate of Formestane which could result in a higher serum level.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Ketamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ketamine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FosfomycinKetamine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.Approved
FosinoprilFosinopril may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
FosphenytoinThe metabolism of Ketamine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Ketamine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Ketamine is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Furazolidone.Approved, Investigational, Vet Approved
FurosemideFurosemide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ketamine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketamine.Approved, Investigational
Gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ketamine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Ketamine is combined with Gaboxadol.Investigational
Gadobenic acidGadobenic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
GadodiamideGadodiamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Gadofosveset trisodiumKetamine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.Approved
Gadopentetic acidGadopentetic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Gadoteric acidKetamine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.Approved
GadoteridolGadoteridol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
GalantamineKetamine may decrease the excretion rate of Galantamine which could result in a higher serum level.Approved
GallamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Ketamine is combined with Gallamine Triethiodide.Approved
Gamma hydroxybutyric acidThe risk or severity of adverse effects can be increased when Ketamine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Ketamine is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Ketamine is combined with Gedocarnil.Experimental
GemcitabineGemcitabine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
GemeprostKetamine may decrease the excretion rate of Gemeprost which could result in a higher serum level.Approved, Withdrawn
GemfibrozilKetamine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.Approved
GeneticinThe risk or severity of adverse effects can be increased when Ketamine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Ketamine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Ketamine is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Ketamine is combined with Gepirone.Investigational
GimeracilKetamine may decrease the excretion rate of Gimeracil which could result in a higher serum level.Approved
GlipizideGlipizide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ketamine is combined with Glutethimide.Approved, Illicit
Glycerol phenylbutyrateKetamine may decrease the excretion rate of Glycerol Phenylbutyrate which could result in a higher serum level.Approved
GoserelinGoserelin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
GranisetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Granisetron.Approved, Investigational
GuacetisalGuacetisal may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
GuanethidineGuanethidine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Ketamine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketamine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ketamine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Ketamine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Heptabarbital.Approved
HeroinThe risk or severity of adverse effects can be increased when Ketamine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Hydracarbazine.Experimental
HydralazineKetamine may decrease the excretion rate of Hydralazine which could result in a higher serum level.Approved
HydrocodoneKetamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HydrocortisoneThe metabolism of Ketamine can be increased when combined with Hydrocortisone.Approved, Vet Approved
Hydrolyzed CephalothinHydrolyzed Cephalothin may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketamine.Approved, Illicit
HydroxocobalaminHydroxocobalamin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Hydroxyethyl StarchKetamine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Ketamine is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Ketamine is combined with Hypericin.Investigational
IbuprofenIbuprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
IbutilideIbutilide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
IcatibantKetamine may decrease the excretion rate of Icatibant which could result in a higher serum level.Approved, Investigational
IcosapentIcosapent may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Nutraceutical
IdalopirdineThe risk or severity of adverse effects can be increased when Ketamine is combined with Idalopirdine.Investigational
IdarucizumabKetamine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.Approved
IdebenoneKetamine may decrease the excretion rate of Idebenone which could result in a higher serum level.Approved, Investigational
IdelalisibThe metabolism of Ketamine can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Ketamine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Iferanserin.Investigational
IfosfamideIfosfamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Ketamine is combined with Imagabalin.Investigational
ImatinibThe metabolism of Ketamine can be decreased when combined with Imatinib.Approved
ImidafenacinKetamine may decrease the excretion rate of Imidafenacin which could result in a higher serum level.Approved, Investigational
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Imipramine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Ketamine is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Ketamine is combined with Indalpine.Investigational, Withdrawn
IndapamideKetamine may decrease the excretion rate of Indapamide which could result in a higher serum level.Approved
Indigotindisulfonic AcidKetamine may decrease the excretion rate of Indigotindisulfonic Acid which could result in a higher serum level.Approved
IndinavirThe metabolism of Ketamine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Ketamine is combined with Indiplon.Investigational
IndobufenIndobufen may decrease the excretion rate of Ketamine which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
Inosine pranobexKetamine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.Approved
InositolKetamine may decrease the excretion rate of Inositol which could result in a higher serum level.Approved, Investigational, Withdrawn
Invert sugarKetamine may decrease the excretion rate of Invert sugar which could result in a higher serum level.Approved
Iobenguane sulfate I-123Ketamine may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.Approved, Investigational
IodixanolKetamine may decrease the excretion rate of Iodixanol which could result in a higher serum level.Approved
Ioflupane I-123Ketamine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.Approved
IopromideKetamine may decrease the excretion rate of Iopromide which could result in a higher serum level.Approved
Iothalamic acidKetamine may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.Approved
IoversolKetamine may decrease the excretion rate of Ioversol which could result in a higher serum level.Approved
IoxilanKetamine may decrease the excretion rate of Ioxilan which could result in a higher serum level.Approved
IpecacKetamine may decrease the excretion rate of Ipecac which could result in a higher serum level.Approved, Withdrawn
IpilimumabKetamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Ketamine is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Ketamine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Ketamine is combined with Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Ketamine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Ketamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Ketamine is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Ketamine is combined with Isocarboxazid.Approved
IsoflavoneKetamine may decrease the excretion rate of Isoflavone which could result in a higher serum level.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ketamine.Approved, Vet Approved
IsoniazidThe metabolism of Ketamine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide MononitrateIsosorbide Mononitrate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Isosulfan blueKetamine may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.Approved
IsotretinoinKetamine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.Approved
IsoxicamIsoxicam may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
IsradipineIsradipine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
ItraconazoleThe metabolism of Ketamine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ketamine can be increased when it is combined with Ivacaftor.Approved
IxazomibKetamine may decrease the excretion rate of Ixazomib which could result in a higher serum level.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneKebuzone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Ketamine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
L-CarnitineL-Carnitine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Ketamine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolKetamine may decrease the excretion rate of Labetalol which could result in a higher serum level.Approved
LacosamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Lacosamide.Approved
LamivudineLamivudine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lamotrigine.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Ketamine is combined with Lasmiditan.Investigational
LatamoxefLatamoxef may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Latanoprostene BunodKetamine may decrease the excretion rate of Latanoprostene Bunod which could result in a higher serum level.Approved, Investigational
LedipasvirKetamine may decrease the excretion rate of Ledipasvir which could result in a higher serum level.Approved
LenalidomideLenalidomide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
LesinuradKetamine may decrease the excretion rate of Lesinurad which could result in a higher serum level.Approved, Investigational
LeuprolideLeuprolide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ketamine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineLevobupivacaine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ketamine is combined with Levodopa.Approved
LevofloxacinLevofloxacin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Levomethadyl acetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ketamine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketamine.Approved
LevosalbutamolKetamine may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.Approved, Investigational
LincomycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Ketamine is combined with Linezolid.Approved, Investigational
LisinoprilLisinopril may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Ketamine is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Ketamine is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Ketamine is combined with Lithium cation.Experimental
LixisenatideKetamine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ketamine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Ketamine can be increased when used in combination with Lofexidine.Approved, Investigational
LonazolacLonazolac may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
LopinavirThe metabolism of Ketamine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Ketamine is combined with Loprazolam.Experimental
LoracarbefLoracarbef may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketamine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Lormetazepam.Approved
LornoxicamLornoxicam may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LorpiprazoleThe serum concentration of Ketamine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lortalamine.Experimental
LovastatinThe metabolism of Ketamine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketamine.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LubiprostoneLubiprostone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LuliconazoleThe serum concentration of Ketamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ketamine can be decreased when it is combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Lumateperone.Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Ketamine is combined with m-Chlorophenylpiperazine.Investigational
MacitentanKetamine may decrease the excretion rate of Macitentan which could result in a higher serum level.Approved
MafenideKetamine may decrease the excretion rate of Mafenide which could result in a higher serum level.Approved, Vet Approved
Magnesium acetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium phosphate.Experimental
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Ketamine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Ketamine is combined with Magnesium Trisilicate.Approved
MangafodipirKetamine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.Approved, Investigational, Withdrawn
ManidipineThe serum concentration of Ketamine can be increased when it is combined with Manidipine.Approved, Investigational
MannitolMannitol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Ketamine is combined with Maprotiline.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Ketamine is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Ketamine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Meclizine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Medifoxamine.Experimental
Medroxyprogesterone acetateMedroxyprogesterone acetate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Mefenamic acidMefenamic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Megestrol acetateMegestrol acetate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Ketamine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Ketamine is combined with Melitracen.Experimental, Investigational
MeloxicamMeloxicam may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Melperone.Approved, Investigational
MemantineThe risk or severity of adverse effects can be increased when Ketamine is combined with Memantine.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Ketamine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Mephenoxalone.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Ketamine is combined with Mephenytoin.Approved, Investigational, Withdrawn
MepivacaineMepivacaine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ketamine is combined with Meptazinol.Experimental
MeropenemMeropenem may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
MersalylKetamine may decrease the excretion rate of Mersalyl which could result in a higher serum level.Approved
MesalazineMesalazine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Mesoridazine.Approved, Investigational
MetamizoleMetamizole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Ketamine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Ketamine is combined with Metergoline.Experimental
MetforminMetformin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MethacyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ketamine.Approved
Methadyl acetateThe risk or severity of adverse effects can be increased when Ketamine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ketamine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Metharbital.Withdrawn
MethimazoleMethimazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Ketamine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketamine.Approved
MethotrexateMethotrexate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MethotrimeprazineKetamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxsalenMethoxsalen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ketamine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.Approved
MethyldopaMethyldopa may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Ketamine is combined with Methylene blue.Approved, Investigational
MethylnaltrexoneKetamine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.Approved
MethylpentynolThe risk or severity of adverse effects can be increased when Ketamine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Ketamine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Methylphenobarbital.Approved
MethyltestosteroneKetamine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Ketamine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Ketamine is combined with Methysergide.Approved
MetoclopramideKetamine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Ketamine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Ketamine is combined with Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MetyraponeMetyrapone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
MetyrosineKetamine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Mianserin.Approved, Investigational
MibefradilThe metabolism of Ketamine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Ketamine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Ketamine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ketamine.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Ketamine can be increased when it is combined with Mifepristone.Approved, Investigational
MigalastatKetamine may decrease the excretion rate of Migalastat which could result in a higher serum level.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ketamine is combined with Milnacipran.Approved, Investigational
MilrinoneMilrinone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MinaprineThe risk or severity of adverse effects can be increased when Ketamine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Investigational
MirabegronKetamine may decrease the excretion rate of Mirabegron which could result in a higher serum level.Approved
MirtazapineKetamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ketamine can be decreased when it is combined with Mitotane.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Ketamine is combined with Mivacurium.Approved
MK-212The risk or severity of adverse effects can be increased when Ketamine is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Ketamine is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Ketamine is combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Ketamine can be decreased when it is combined with Modafinil.Approved, Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Ketamine is combined with Moricizine.Approved, Investigational, Withdrawn
MorniflumateMorniflumate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ketamine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Mosapride.Investigational
MoxisylyteKetamine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.Approved, Investigational
MRK-409The risk or severity of adverse effects can be increased when Ketamine is combined with MRK-409.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Ketamine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
N-acetyltyrosineKetamine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.Approved
N-MethylnicotinamideKetamine may decrease the excretion rate of N-Methylnicotinamide which could result in a higher serum level.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Investigational
NabumetoneNabumetone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
NadololNadolol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
NafcillinThe serum concentration of Ketamine can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Ketamine is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketamine.Approved
NaldemedineKetamine may decrease the excretion rate of Naldemedine which could result in a higher serum level.Approved, Investigational
NalmefeneKetamine may decrease the excretion rate of Nalmefene which could result in a higher serum level.Approved, Investigational, Withdrawn
NaloxoneThe metabolism of Ketamine can be decreased when combined with Naloxone.Approved, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Ketamine is combined with Naluzotan.Investigational
NaproxenNaproxen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Naronapride.Investigational
NateglinideNateglinide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
NeamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Neamine.Experimental
NedaplatinKetamine may decrease the excretion rate of Nedaplatin which could result in a higher serum level.Approved, Investigational
NedocromilNedocromil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Ketamine is combined with Nefiracetam.Investigational
NelfinavirThe metabolism of Ketamine can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Ketamine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Ketamine is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Ketamine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Ketamine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Niaprazine.Experimental
NicardipineThe metabolism of Ketamine can be decreased when combined with Nicardipine.Approved, Investigational
NicoboxilKetamine may decrease the excretion rate of Nicoboxil which could result in a higher serum level.Approved, Investigational
NicorandilKetamine may decrease the excretion rate of Nicorandil which could result in a higher serum level.Approved, Investigational
NifedipineNifedipine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
NilotinibThe metabolism of Ketamine can be decreased when combined with Nilotinib.Approved, Investigational
NilutamideKetamine may decrease the excretion rate of Nilutamide which could result in a higher serum level.Approved, Investigational
NimesulideNimesulide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Withdrawn
NisoldipineNisoldipine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
NisoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrazepam.Approved
Nitric OxideNitric Oxide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
NitroaspirinNitroaspirin may decrease the excretion rate of Ketamine which could result in a higher serum level.Investigational
NitroprussideNitroprusside may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Ketamine is combined with Nitrous oxide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Nordazepam.Approved
NorgestimateThe metabolism of Ketamine can be increased when combined with Norgestimate.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Nortriptyline.Approved
NS-398NS-398 may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
OctamoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Octamoxin.Withdrawn
OctinoxateKetamine may decrease the excretion rate of Octinoxate which could result in a higher serum level.Approved, Investigational
OctreotideThe metabolism of Ketamine can be decreased when combined with Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ketamine.Approved, Investigational
OlaparibThe metabolism of Ketamine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ketamine is combined with Olopatadine.Approved
OlsalazineOlsalazine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
OmeprazoleOmeprazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Ketamine is combined with Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Ketamine is combined with Opium.Approved, Illicit
OrphenadrineKetamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Ketamine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Ketamine is combined with Osanetant.Investigational
OseltamivirOseltamivir may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
OsimertinibThe serum concentration of Ketamine can be increased when it is combined with Osimertinib.Approved
Oxabolone cipionateKetamine may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.Experimental
OxacillinOxacillin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxaprotiline.Experimental
OxaprozinOxaprozin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketamine.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxprenolol.Approved
OxybenzoneKetamine may decrease the excretion rate of Oxybenzone which could result in a higher serum level.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketamine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketamine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxypertine.Experimental
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
OxyquinolineKetamine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.Approved, Vet Approved
OxytetracyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Ketamine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Pancuronium.Approved
PantoprazolePantoprazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
ParachlorophenolKetamine may decrease the excretion rate of Parachlorophenol which could result in a higher serum level.Approved
ParaldehydeKetamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Ketamine is combined with Paramethadione.Approved
ParecoxibParecoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
PargylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paroxetine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Ketamine can be decreased when used in combination with Patent Blue.Approved
PegaptanibKetamine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.Approved, Investigational
PeginesatideKetamine may decrease the excretion rate of Peginesatide which could result in a higher serum level.Approved, Investigational
PegvisomantThe metabolism of Ketamine can be increased when combined with Pegvisomant.Approved
PemetrexedPemetrexed may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Ketamine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ketamine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Penimepicycline.Experimental
Pentaerythritol TetranitrateKetamine may decrease the excretion rate of Pentaerythritol Tetranitrate which could result in a higher serum level.Approved
PentamidinePentamidine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PentastarchKetamine may decrease the excretion rate of Pentastarch which could result in a higher serum level.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketamine.Approved, Vet Approved
Pentetic acidKetamine may decrease the excretion rate of Pentetic acid which could result in a higher serum level.Approved
PentobarbitalThe metabolism of Ketamine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinPentostatin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PentoxifyllinePentoxifylline may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
PerazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Ketamine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilKetamine may decrease the excretion rate of Perindopril which could result in a higher serum level.Approved
PermethrinKetamine may decrease the excretion rate of Permethrin which could result in a higher serum level.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ketamine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketamine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketamine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Ketamine is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Ketamine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenoperidine.Experimental
PhenoxyethanolKetamine may decrease the excretion rate of Phenoxyethanol which could result in a higher serum level.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Ketamine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Ketamine is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Ketamine is combined with Phentermine.Approved, Illicit
PhentolamineKetamine may decrease the excretion rate of Phentolamine which could result in a higher serum level.Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
PhenytoinThe metabolism of Ketamine can be increased when combined with Phenytoin.Approved, Vet Approved
PholcodineKetamine may decrease the excretion rate of Pholcodine which could result in a higher serum level.Approved, Illicit
PhosphocreatineKetamine may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.Nutraceutical
Phosphoric acidKetamine may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.Approved
PhylloquinoneKetamine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.Approved, Investigational
PiclozotanThe risk or severity of adverse effects can be increased when Ketamine is combined with Piclozotan.Investigational
Picosulfuric acidKetamine may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.Approved
PidotimodKetamine may decrease the excretion rate of Pidotimod which could result in a higher serum level.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ketamine.Approved
PinazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Pinazepam.Experimental
PindololThe risk or severity of adverse effects can be increased when Ketamine is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipecuronium.Approved
PiperacillinPiperacillin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
PiperaquineThe serum concentration of Ketamine can be increased when it is combined with Piperaquine.Approved, Investigational
Piperonyl butoxideKetamine may decrease the excretion rate of Piperonyl butoxide which could result in a higher serum level.Approved, Vet Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipotiazine.Approved, Investigational
PiracetamKetamine may decrease the excretion rate of Piracetam which could result in a higher serum level.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ketamine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Pirlindole.Approved
PiroxicamPiroxicam may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
PitolisantThe serum concentration of Ketamine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Ketamine is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Ketamine is combined with Plazomicin.Approved, Investigational
PlerixaforKetamine may decrease the excretion rate of Plerixafor which could result in a higher serum level.Approved
Polyethylene glycol 400Ketamine may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Ketamine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ketamine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Ketamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateKetamine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.Approved, Investigational
Potassium bicarbonateKetamine may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.Approved
Potassium cationKetamine may decrease the excretion rate of Potassium cation which could result in a higher serum level.Approved, Investigational
Potassium ChloridePotassium Chloride may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
Potassium nitrateKetamine may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.Approved
Potassium perchlorateKetamine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.Approved, Investigational
Potassium sulfateKetamine may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.Approved, Investigational
PralidoximePralidoxime may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
PramipexoleKetamine may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental, Investigational
PrasugrelKetamine may decrease the excretion rate of Prasugrel which could result in a higher serum level.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Prazepam.Approved, Illicit
PrednisonePrednisone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Ketamine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Ketamine is combined with Pridinol.Experimental
PrimidoneThe metabolism of Ketamine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidProbenecid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
ProcainamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Ketamine is combined with Procaine.Approved, Investigational, Vet Approved
Procaine benzylpenicillinKetamine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketamine.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Ketamine is combined with Progabide.Approved, Investigational
ProglumetacinProglumetacin may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketamine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Promethazine.Approved, Investigational
PropacetamolPropacetamol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Ketamine is combined with Propanidid.Experimental
PropanthelinePropantheline may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Propiopromazine.Vet Approved
PropiverineKetamine may decrease the excretion rate of Propiverine which could result in a higher serum level.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ketamine.Approved, Investigational, Vet Approved
PropranololPropranolol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PropyphenazonePropyphenazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
ProthipendylThe risk or severity of adverse effects can be increased when Ketamine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ketamine is combined with Proxibarbal.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Ketamine is combined with PRX-08066.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Ketamine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Ketamine is combined with Pyrantel.Approved, Vet Approved
PyrazinamidePyrazinamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
PyridoxinePyridoxine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Nutraceutical, Vet Approved
PyrithioneKetamine may decrease the excretion rate of Pyrithione which could result in a higher serum level.Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Ketamine is combined with Pyrithyldione.Experimental
QuazepamThe serum concentration of Ketamine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Ketamine is combined with Quetiapine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Ketamine can be increased when combined with Quinine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Quinupramine.Experimental
RabeprazoleRabeprazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ketamine is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Ramosetron.Approved, Investigational
RanitidineRanitidine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
RapacuroniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Rapacuronium.Approved, Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Ketamine is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Ketamine can be increased when it is combined with Regorafenib.Approved
RemacemideThe risk or severity of adverse effects can be increased when Ketamine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketamine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Ketamine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Ketamine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ketamine.Approved, Investigational
ResorcinolKetamine may decrease the excretion rate of Resorcinol which could result in a higher serum level.Approved
RibavirinRibavirin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
RibostamycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Ketamine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Ketamine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Ketamine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Ketamine can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Ketamine can be increased when it is combined with Rilpivirine.Approved
RiluzoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Ketamine can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketamine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Ketamine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanKetamine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Rizatriptan.Approved
RobenacoxibRobenacoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental, Vet Approved
RocuroniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Withdrawn
RoflumilastKetamine may decrease the excretion rate of Roflumilast which could result in a higher serum level.Approved
RolipramThe risk or severity of adverse effects can be increased when Ketamine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Romifidine.Vet Approved
RopiniroleKetamine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
RosiglitazoneRosiglitazone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
RotigotineKetamine may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Ketamine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ketamine.Approved
RuxolitinibKetamine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.Approved
SacubitrilKetamine may decrease the excretion rate of Sacubitril which could result in a higher serum level.Approved
SafinamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Safrazine.Withdrawn
SalbutamolSalbutamol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
SalicylamideSalicylamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
Salmon CalcitoninSalmon Calcitonin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
SalsalateSalsalate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
SaquinavirThe metabolism of Ketamine can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Ketamine is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Ketamine can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Ketamine is combined with Sarpogrelate.Investigational
SaxagliptinKetamine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.Approved
SC-236SC-236 may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketamine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Ketamine is combined with Selegiline.Approved, Investigational, Vet Approved
Selenious acidKetamine may decrease the excretion rate of Selenious acid which could result in a higher serum level.Approved, Investigational
SeleniumKetamine may decrease the excretion rate of Selenium which could result in a higher serum level.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Ketamine is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Ketamine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Ketamine is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Sildenafil can be decreased when combined with Ketamine.Approved, Investigational
SiltuximabThe serum concentration of Ketamine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ketamine can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Ketamine is combined with Sisomicin.Investigational
SitagliptinKetamine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.Approved, Investigational
Sodium acetateKetamine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.Approved, Investigational
Sodium aurothiomalateKetamine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.Approved, Investigational
Sodium fluorideKetamine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
Sodium sulfateKetamine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.Approved, Vet Approved
SofosbuvirKetamine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.Approved
SorafenibSorafenib may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
SorbitolKetamine may decrease the excretion rate of Sorbitol which could result in a higher serum level.Approved
SpironolactoneSpironolactone may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.Approved
St. John's WortThe serum concentration of Ketamine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ketamine can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Streptomycin.Approved, Vet Approved
Strontium chlorideKetamine may decrease the excretion rate of Strontium chloride which could result in a higher serum level.Approved
StyramateThe risk or severity of adverse effects can be increased when Ketamine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Ketamine is combined with Succinylcholine.Approved
SucralfateSucralfate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.Approved, Investigational
SulbactamKetamine may decrease the excretion rate of Sulbactam which could result in a higher serum level.Approved
SulfadiazineSulfadiazine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
SulfasalazineSulfasalazine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
SulisobenzoneKetamine may decrease the excretion rate of Sulisobenzone which could result in a higher serum level.Approved
SulpirideThe risk or severity of adverse effects can be increased when Ketamine is combined with Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Ketamine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Sumatriptan.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Withdrawn
SuvorexantKetamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneSuxibuzone may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
Synthetic Conjugated Estrogens, AKetamine may decrease the excretion rate of Synthetic Conjugated Estrogens, A which could result in a higher serum level.Approved
Synthetic Conjugated Estrogens, BKetamine may decrease the excretion rate of Synthetic Conjugated Estrogens, B which could result in a higher serum level.Approved
TacrolimusTacrolimus may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TadalafilTadalafil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Ketamine is combined with Talbutal.Approved, Illicit
TalniflumateTalniflumate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
TalopramThe risk or severity of adverse effects can be increased when Ketamine is combined with Talopram.Experimental
TamsulosinTamsulosin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ketamine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ketamine is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Ketamine is combined with TD-8954.Investigational
Technetium Tc-99m disofeninKetamine may decrease the excretion rate of Technetium Tc-99m disofenin which could result in a higher serum level.Approved
Technetium Tc-99m exametazimeKetamine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.Approved
Technetium Tc-99m mebrofeninKetamine may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.Approved
Technetium Tc-99m oxidronateKetamine may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.Approved
Technetium Tc-99m pyrophosphateKetamine may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.Approved
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Ketamine is combined with Tedizolid phosphate.Approved
TeduglutideKetamine may decrease the excretion rate of Teduglutide which could result in a higher serum level.Approved
TegafurKetamine may decrease the excretion rate of Tegafur which could result in a higher serum level.Approved, Investigational
TegaserodThe risk or severity of adverse effects can be increased when Ketamine is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Ketamine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinKetamine may decrease the excretion rate of Telavancin which could result in a higher serum level.Approved
TelithromycinThe metabolism of Ketamine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketamine.Approved, Investigational
TemozolomideTemozolomide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TenidapTenidap may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental
TenofovirTenofovir may decrease the excretion rate of Ketamine which could result in a higher serum level.Experimental, Investigational
Tenofovir alafenamideTenofovir alafenamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
Tenofovir disoproxilTenofovir disoproxil may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Ketamine which could result in a higher serum level.Vet Approved
TerbinafineThe metabolism of Ketamine can be increased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
TestolactoneTestolactone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TestosteroneTestosterone may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
Testosterone cypionateKetamine may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.Approved
Testosterone enanthateKetamine may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.Approved
Testosterone propionateKetamine may decrease the excretion rate of Testosterone propionate which could result in a higher serum level.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateKetamine may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetracycline.Approved, Vet Approved
Tetradecyl hydrogen sulfate (ester)Ketamine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrahydropalmatine.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Ketamine is combined with Tetrodotoxin.Investigational
ThalidomideKetamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiabendazoleThiabendazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
ThiamylalThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiocolchicoside.Approved, Investigational
ThiopropazateThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketamine.Approved, Withdrawn
ThiotepaThe serum concentration of Ketamine can be increased when it is combined with Thiotepa.Approved, Investigational
ThiothixeneThe risk or severity of adverse effects can be increased when Ketamine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiapride.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
TiclopidineThe serum concentration of Ketamine can be increased when it is combined with Ticlopidine.Approved
TigecyclineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tilidine.Experimental
Tiludronic acidTiludronic acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Vet Approved
TimololTimolol may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
TinidazoleTinidazole may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TinoridineTinoridine may decrease the excretion rate of Ketamine which could result in a higher serum level.Investigational
TioproninKetamine may decrease the excretion rate of Tiopronin which could result in a higher serum level.Approved, Investigational
TiotropiumKetamine may decrease the excretion rate of Tiotropium which could result in a higher serum level.Approved
TipranavirThe metabolism of Ketamine can be decreased when combined with Tipranavir.Approved, Investigational
TirofibanTirofiban may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
TixocortolKetamine may decrease the excretion rate of Tixocortol which could result in a higher serum level.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Ketamine can be decreased when it is combined with Tocilizumab.Approved
TocopherolKetamine may decrease the excretion rate of Tocopherol which could result in a higher serum level.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Ketamine is combined with Tofisopam.Approved
TolazamideTolazamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TolbutamideTolbutamide may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Ketamine is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TolmetinTolmetin may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Tolperisone.Approved, Investigational
TolterodineTolterodine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Ketamine is combined with Topiramate.Approved
TopiroxostatKetamine may decrease the excretion rate of Topiroxostat which could result in a higher serum level.Approved, Investigational
TopotecanTopotecan may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TositumomabTositumomab may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketamine.Approved, Investigational
TrametinibKetamine may decrease the excretion rate of Trametinib which could result in a higher serum level.Approved
TramiprosateThe risk or severity of adverse effects can be increased when Ketamine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Trazodone.Approved, Investigational
TriamcinoloneThe metabolism of Ketamine can be increased when combined with Triamcinolone.Approved, Vet Approved
TriamtereneTriamterene may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketamine.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ketamine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ketamine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Ketamine is combined with Triclofos.Withdrawn
TriethylenetetramineKetamine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.Approved, Investigational
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ketamine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ketamine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Triflupromazine.Approved, Vet Approved
TrifluridineTrifluridine may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
TrimebutineKetamine may decrease the excretion rate of Trimebutine which could result in a higher serum level.Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Ketamine is combined with Trimethadione.Approved
TrimethoprimTrimethoprim may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Vet Approved
TrimetrexateKetamine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Ketamine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Triprolidine.Approved
TrolamineKetamine may decrease the excretion rate of Trolamine which could result in a higher serum level.Approved
Trolamine salicylateTrolamine salicylate may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved
TroleandomycinThe metabolism of Ketamine can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Ketamine is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tubocurarine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Ketamine is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Ketamine is combined with Vabicaserin.Investigational
VaborbactamKetamine may decrease the excretion rate of Vaborbactam which could result in a higher serum level.Approved, Investigational
ValaciclovirValaciclovir may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
ValbenazineKetamine may decrease the excretion rate of Valbenazine which could result in a higher serum level.Approved, Investigational
ValdecoxibValdecoxib may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational, Withdrawn
ValerianThe risk or severity of adverse effects can be increased when Ketamine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Ketamine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Ketamine is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Ketamine is combined with Vancomycin.Approved
VareniclineKetamine may decrease the excretion rate of Varenicline which could result in a higher serum level.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Ketamine is combined with Vecuronium.Approved
VemurafenibThe serum concentration of Ketamine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Ketamine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ketamine is combined with Veralipride.Experimental
VerapamilThe metabolism of Ketamine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ketamine is combined with Vigabatrin.Approved
VilanterolKetamine may decrease the excretion rate of Vilanterol which could result in a higher serum level.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Ketamine is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Ketamine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Ketamine is combined with Vinylbital.Experimental
VoriconazoleThe metabolism of Ketamine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vortioxetine.Approved, Investigational
WarfarinKetamine may decrease the excretion rate of Warfarin which could result in a higher serum level.Approved
WortmanninThe risk or severity of adverse effects can be increased when Ketamine is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Ketamine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Ketamine is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Ketamine is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Ketamine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketamine.Approved, Illicit, Investigational
ZaltoprofenZaltoprofen may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
ZanamivirZanamivir may decrease the excretion rate of Ketamine which could result in a higher serum level.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ketamine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ketamine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ketamine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Ketamine is combined with Zolmitriptan.Approved, Investigational
ZolpidemKetamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the excretion rate of Ketamine which could result in a higher serum level.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Ketamine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ketamine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ketamine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ketamine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

John A. Flores, Kenton L. Crowley, "Process for the preparation of ketamine ointment." U.S. Patent US5817699, issued June, 1995.

US5817699
General References
  1. Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. [PubMed:2858237]
  2. Bergman SA: Ketamine: review of its pharmacology and its use in pediatric anesthesia. Anesth Prog. 1999 Winter;46(1):10-20. [PubMed:10551055]
  3. Bonanno FG: Ketamine in war/tropical surgery (a final tribute to the racemic mixture). Injury. 2002 May;33(4):323-7. [PubMed:12091028]
  4. Lankenau SE, Sanders B, Bloom JJ, Hathazi D, Alarcon E, Tortu S, Clatts MC: First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug Alcohol Depend. 2007 Mar 16;87(2-3):183-93. Epub 2006 Sep 18. [PubMed:16979848]
  5. Reboso Morales JA, Gonzalez Miranda F: [Ketamine]. Rev Esp Anestesiol Reanim. 1999 Mar;46(3):111-22. [PubMed:10228376]
  6. Ivani G, Vercellino C, Tonetti F: Ketamine: a new look to an old drug. Minerva Anestesiol. 2003 May;69(5):468-71. [PubMed:12768186]
  7. Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, Hu H: Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018 Feb 14;554(7692):317-322. doi: 10.1038/nature25509. [PubMed:29446381]
  8. Kirby T: Ketamine for depression: the highs and lows. Lancet Psychiatry. 2015 Sep;2(9):783-4. doi: 10.1016/S2215-0366(15)00392-2. [PubMed:26360893]
  9. Xu J, Lei H: Ketamine-an update on its clinical uses and abuses. CNS Neurosci Ther. 2014 Dec;20(12):1015-20. doi: 10.1111/cns.12363. [PubMed:25417928]
  10. Clements JA, Nimmo WS, Grant IS: Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982 May;71(5):539-42. [PubMed:7097501]
  11. Fanta S, Kinnunen M, Backman JT, Kalso E: Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015 Apr;71(4):441-7. doi: 10.1007/s00228-015-1826-y. Epub 2015 Mar 1. [PubMed:25724645]
  12. Kaka JS, Hayton WL: Pharmacokinetics of ketamine and two metabolites in the dog. J Pharmacokinet Biopharm. 1980 Apr;8(2):193-202. [PubMed:7431222]
  13. Pypendop BH, Ilkiw JE: Pharmacokinetics of ketamine and its metabolite, norketamine, after intravenous administration of a bolus of ketamine to isoflurane-anesthetized dogs. Am J Vet Res. 2005 Dec;66(12):2034-8. doi: 10.2460/ajvr.2005.66.2034. [PubMed:16379643]
  14. Ketamine [Link]
  15. Ketamine monograph [Link]
  16. Time magazine [Link]
External Links
Human Metabolome Database
HMDB0015352
KEGG Drug
D08098
KEGG Compound
C07525
PubChem Compound
3821
PubChem Substance
46508295
ChemSpider
3689
BindingDB
50044140
ChEBI
6121
ChEMBL
CHEMBL742
Therapeutic Targets Database
DAP001148
PharmGKB
PA450144
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ketamine
ATC Codes
N01AX03 — Ketamine
AHFS Codes
  • 28:04.00 — General Anesthetics
  • 28:04.92 — Miscellaneous General Anesthetics
FDA label
Download (228 KB)
MSDS
Download (67.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceDepression1
0Active Not RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
0Active Not RecruitingSupportive CareHemorrhoids / Perianal Fistulas1
0Active Not RecruitingTreatmentCancers / Depression / Head and Neck Carcinoma1
0Active Not RecruitingTreatmentSocial Anxiety Disorder (SAD)1
0CompletedPreventionDepression1
0CompletedTreatmentBipolar I Disorder / Bipolar II Disorder / Depression, Bipolar / Major Depressive Disorder (MDD) / Suicidal Ideation1
0Not Yet RecruitingPreventionPost-Mastectomy Chronic Pain Syndrome / Postoperative pain1
0Not Yet RecruitingTreatmentDistal Radius Fractures / Sedation, Conscious1
0Not Yet RecruitingTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
0RecruitingTreatmentCancers / Ketamine / Tiredness1
0RecruitingTreatmentLumbar Spinal Instability / Lumbar Spine Degeneration / Spinal Stenosis of Lumbar Region1
0WithdrawnPreventionDepression / Head and Neck Carcinoma / Malignant Neoplasm of Pancreas1
1Active Not RecruitingBasic ScienceCognitive Symptom / Schizophrenic Disorders1
1Active Not RecruitingBasic ScienceHealthy Volunteers2
1Active Not RecruitingBasic SciencePsychiatric Disorder NOS1
1Active Not RecruitingTreatmentPain1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableSchizophrenic Disorders1
1CompletedBasic ScienceChanges in Striatal [11C]ORM-13070 Binding1
1CompletedBasic ScienceConfusion and disorientation / Perceptual Disorders / Schizophrenic Disorders1
1CompletedBasic ScienceDepression1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceKetamine-Induced Brain Activity Changes / Psychotic-like Symptoms1
1CompletedBasic ScienceSchizophrenic Disorders2
1CompletedSupportive CarePostoperative pain1
1CompletedTreatmentAlcohol Dependence / Depression1
1CompletedTreatmentCortical Spreading Depolarization / Cortical Spreading Depression / Subarachoid Hemorrhage / Traumatic Brain Injury (TBI)1
1CompletedTreatmentDepression1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMajor Depressive Disorder (MDD)1
1CompletedTreatmentPain1
1CompletedTreatmentPain, Chronic1
1CompletedTreatmentSchizophrenic Disorders1
1Enrolling by InvitationBasic ScienceBipolar I Disorder / Bipolar II Disorder / Major Depressive Disorder (MDD) / Unipolar Depression1
1Not Yet RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
1RecruitingOtherDepression, Bipolar / Major Depressive Episode / Unipolar Depression1
1RecruitingOtherMagnetic Resonance Imaging (MRI)1
1RecruitingTreatmentAcute Pain Management / Amputation of Lower Extremity, All Causes / Analgesic, Nonopioid1
1RecruitingTreatmentAutism Spectrum Conditions/Disorders1
1RecruitingTreatmentDepression / Healthy Volunteers / Major Depressive Disorder (MDD)1
1RecruitingTreatmentDepressive Disorder, Treatment-Resistant / Stress Disorders, Post-Traumatic1
1RecruitingTreatmentMajor Depressive Disorder (MDD)1
1RecruitingTreatmentUnipolar Depression1
1TerminatedNot AvailableOpioid Tolerance / Sedation therapy1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedOtherDepression / Depressive Disorder, Recurrent / Major Depressive Disorder (MDD) / Relapses1
1TerminatedTreatmentAcute Depression1
1Unknown StatusTreatmentPain / Traumatic Limb Injury1
1Unknown StatusTreatmentPharmacokinetics1
1WithdrawnBasic ScienceDrug Abuse / Healthy Volunteers1
1, 2Active Not RecruitingTreatmentBipolar Disorder (BD) / Major Depressive Episode / Suicidal Ideation1
1, 2CompletedNot AvailableCognitive Dysfunctions1
1, 2CompletedOtherDepression / Depression, Bipolar / Major Depresssion / Moods Disorders1
1, 2CompletedPreventionPost Operative Pain1
1, 2CompletedTreatmentObsessive-Compulsive Disorder (OCD)1
1, 2CompletedTreatmentPain, Acute / Pain, Chronic1
1, 2RecruitingSupportive CareCancers / Pain1
1, 2RecruitingTreatmentAlcohol Use Disorder (AUD) / Major Depressive Disorder (MDD)1
1, 2RecruitingTreatmentDepression1
1, 2RecruitingTreatmentDisseminated Sclerosis / Tiredness1
1, 2RecruitingTreatmentStrokes1
1, 2TerminatedTreatmentDependence, Cocaine1
1, 2TerminatedTreatmentObsessive Compulsive Disorder (OCD)1
1, 2TerminatedTreatmentSuicidal Ideas1
1, 2Unknown StatusPreventionTonsillectomy1
1, 2Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
1, 2Unknown StatusTreatmentSepsis1
2Active Not RecruitingOtherDepression1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
2Active Not RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
2Active Not RecruitingTreatmentTreatment Resistant Depression (TRD)1
2CompletedNot AvailableObsessive-Compulsive Disorder (OCD)1
2CompletedBasic ScienceAnaesthesia therapy1
2CompletedPreventionPostoperative pain1
2CompletedPreventionStrabismus1
2CompletedPreventionVentricular Septal Defects1
2CompletedSupportive CareDental Anxiety1
2CompletedSupportive CarePain, Neuropathic1
2CompletedSupportive CarePostoperative Cognitive Dysfunction1
2CompletedTreatmentAlcohol Use Disorder (AUD) / Major Depressive Disorder (MDD)1
2CompletedTreatmentAnaesthesia therapy / Hysterectomy / Ketamine / Morphine1
2CompletedTreatmentAnxiety Disorders / Depression / PTSD / Stress Disorders, Post-Traumatic1
2CompletedTreatmentCancer, Breast / General Surgery1
2CompletedTreatmentCocaine Dependence Related Impairments in Motivation for Change, and in Cue-induced Arousal / Dependence, Cocaine1
2CompletedTreatmentComplex Regional Pain Syndrome (CRPS)1
2CompletedTreatmentDepression2
2CompletedTreatmentDepression / Suicide1
2CompletedTreatmentFusion of Spine (Disease)1
2CompletedTreatmentLaceration1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMajor Depressive Disorder (MDD)2
2CompletedTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
2CompletedTreatmentMucositis1
2CompletedTreatmentObsessive-Compulsive Disorder (OCD)2
2CompletedTreatmentPain3
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentProgressive Infantile Idiopathic Scoliosis1
2CompletedTreatmentTreatment Resistant Depression (TRD)1
2Enrolling by InvitationTreatmentBipolar Disorder (BD) / Major Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
2Not Yet RecruitingBasic ScienceSevere Depression1
2Not Yet RecruitingTreatmentHead Trauma1
2Not Yet RecruitingTreatmentMajor Depressive Episode1
2Not Yet RecruitingTreatmentRett's Syndrome1
2Not Yet RecruitingTreatmentSuicidal Ideation / Suicide1
2RecruitingBasic ScienceAnesthesia Awareness1
2RecruitingBasic ScienceDepression / Healthy Volunteers1
2RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
2RecruitingPreventionSedation During Spinal Anesthesia1
2RecruitingSupportive CareHead and Neck Carcinoma / Mucositis1
2RecruitingTreatmentAdministration and Dosage of Ketamine / Endoscopic Sedation1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders1
2RecruitingTreatmentBorderline Personality Disorder (BPD)1
2RecruitingTreatmentCancers / Depression / Palliative Care1
2RecruitingTreatmentDepression1
2RecruitingTreatmentDepression, Bipolar / Suicidal Ideas / Suicidal Ideation / Suicide, Attempted1
2RecruitingTreatmentDepressive Disorders / Major depressive disorder, recurrent episode1
2RecruitingTreatmentFractures, Bone1
2RecruitingTreatmentKetamine / Laparoscopic Gastric Bypass Surgery1
2RecruitingTreatmentKetamine / Refractory Cancer Pain1
2RecruitingTreatmentKetamine / Violent Aggressive Behavior1
2RecruitingTreatmentLaceration1
2RecruitingTreatmentMajor Depressive Disorder (MDD)2
2RecruitingTreatmentMajor depressive disorder, recurrent episode1
2RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
2RecruitingTreatmentPosttraumatic Stress Disorders / PTSD1
2RecruitingTreatmentPain, Neuropathic1
2RecruitingTreatmentPostoperative pain1
2RecruitingTreatmentPosttraumatic Stress Disorders1
2RecruitingTreatmentPrimary Alcohol Use Disorder1
2RecruitingTreatmentSickle Cell Disorders / Vaso-Occlusive Crises1
2RecruitingTreatmentTraumas1
2TerminatedSupportive CareCancers / Depression / Feeling Anxious1
2TerminatedTreatmentAlcoholism / Magnetic Resonance Imaging (MRI) / Major Depressive Disorder (MDD)1
2TerminatedTreatmentComplex Regional Pain Syndrome (CRPS)1
2TerminatedTreatmentDepressive Disorders1
2TerminatedTreatmentMajor Depressive Disorder (MDD)2
2TerminatedTreatmentObsessive-Compulsive Disorder (OCD)1
2TerminatedTreatmentPain, Chronic1
2TerminatedTreatmentPruritus1
2TerminatedTreatmentSickle Cell Disorders1
2Unknown StatusTreatmentMajor Depressive Episode1
2WithdrawnBasic ScienceTreatment Resistant Depression (TRD)1
2WithdrawnSupportive CarePatients With "ASA 3" Designation / Patients With ASA 3 Designation1
2WithdrawnTreatmentDepression, Bipolar1
2WithdrawnTreatmentTraumatic Brain Injury (TBI)1
2, 3Active Not RecruitingTreatmentPain Management / Therapies1
2, 3CompletedTreatmentAnalgesia, Postoperative / Lower Abdominal Cancer1
2, 3CompletedTreatmentDiseases of the Digestive System / Pain, Acute / Respiratory Tract Diseases1
2, 3CompletedTreatmentFemale Genital Diseases1
2, 3CompletedTreatmentMajor depressive disorder, recurrent episode1
2, 3CompletedTreatmentPain / Post Operative Pain1
2, 3CompletedTreatmentPostoperative pain3
2, 3Not Yet RecruitingBasic ScienceAnaesthesia therapy1
2, 3Not Yet RecruitingTreatmentAcute Ischemic Stroke (AIS)1
2, 3Not Yet RecruitingTreatmentDepression / Pain, Acute1
2, 3RecruitingPreventionObstructive Sleep Apnea (OSA) / Postoperative Complications / Sleep Apnea Syndrome1
2, 3RecruitingPreventionRefractory Epilepsy1
2, 3RecruitingTreatmentAsthma Bronchial / Bronchospasm / Critical Illness1
2, 3RecruitingTreatmentDepression1
2, 3RecruitingTreatmentDepression / Electroconvulsive Therapy / Ketamine / Major Depressive Disorder (MDD) / Major Depressive Episode / Psychiatric Disorders / Treatment Resistant Depression (TRD) / Unipolar Depression1
2, 3RecruitingTreatmentDepression / Suicidal Ideation / Suicidal Impulses1
2, 3RecruitingTreatmentMajor Depressive Disorder (MDD)1
2, 3RecruitingTreatmentPain, Chronic / Rotator Cuff Tendinitis1
2, 3RecruitingTreatmentPain / Postoperative Depression1
2, 3RecruitingTreatmentPostoperative pain1
2, 3RecruitingTreatmentPosttraumatic Stress Disorder (PTSD)1
2, 3RecruitingTreatmentProcedural Sedation1
2, 3RecruitingTreatmentSubarachnoid Hemorrhage1
2, 3TerminatedTreatmentBipolar Disorder (BD)1
2, 3Unknown StatusTreatmentMajor Depressive Disorder (MDD)1
2, 3WithdrawnTreatmentPTSD1
3Active Not RecruitingTreatmentMajor Depressive Disorder (MDD) / Suicidal Ideation1
3Active Not RecruitingTreatmentPain, Chronic2
3Active Not RecruitingTreatmentPain / Traumatic Limb Injury1
3CompletedHealth Services ResearchAbdominal Cancer1
3CompletedPreventionDelirium1
3CompletedPreventionHyperalgesia / Inflammatory Responses / Pain1
3CompletedSupportive CareChronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Neurotoxicity / Pain / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentCancer, Breast / Postoperative pain1
3CompletedTreatmentChronic Post Thoracotomy Pain / Ketamine / Neurocostal neuralgia / Pain / Thoracotomy1
3CompletedTreatmentFractures, Bone1
3CompletedTreatmentHeadaches / Intranasal Ketamine1
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3CompletedTreatmentPain3
3CompletedTreatmentPostoperative pain2
3CompletedTreatmentProcedural Sedation and Analgesia1
3Enrolling by InvitationBasic ScienceMajor Depressive Disorder (MDD)1
3Enrolling by InvitationTreatmentAcute Traumatic Pain1
3Not Yet RecruitingOtherAcute Traumatic Pain1
3Not Yet RecruitingTreatmentAnaesthesia therapy / Shock, Septic1
3Not Yet RecruitingTreatmentDepression, Bipolar / Suicidal Ideation1
3Not Yet RecruitingTreatmentDepression / Suicide1
3Not Yet RecruitingTreatmentFractures, Bone / Joint dislocations1
3Not Yet RecruitingTreatmentPain, Chronic / SC Disease1
3Not Yet RecruitingTreatmentSickle Cell Disorders1
3Not Yet RecruitingTreatmentStatus Asthmaticus1
3RecruitingPreventionAdjunct to general anesthesia therapy / Anaesthesia therapy / Analgesics / Analgesics, Opioid / Dexmedetomidine / Gabapentin / Ketamine / Lidocaine / Narcotics / Obstructive Sleep Apnea of Child / Oximetry, Pulse / Pathologic Processes / Physiologic Effects of Drugs / Postoperative Complications / Respiratory Depression / Sleep Disordered Breathing (SDB) / Tonsillectomy1
3RecruitingPreventionPost Operative Cognitive Dysfunction1
3RecruitingTreatmentAlcohol Abuse / Depression / Suicidal Ideation1
3RecruitingTreatmentCancer: Breakthrough Pain / Cancer: Extreme Pain on Movement1
3RecruitingTreatmentFractures, Closed1
3RecruitingTreatmentInflammatory Reaction / Neurocostal neuralgia / Pain, Chronic1
3RecruitingTreatmentPain Management1
3RecruitingTreatmentPain, Burning1
3RecruitingTreatmentPain, Intractable1
3RecruitingTreatmentShock, Septic1
3RecruitingTreatmentTreatment Resistant Depressive Disorder1
3RecruitingTreatmentRefractory seizure disorders1
3SuspendedTreatmentAlcoholic Patient / Carcinological Surgery ORL1
3TerminatedTreatmentAnaesthesia therapy1
3TerminatedTreatmentAnalgesia, Postoperative / Opioid Free Anaesthesia1
3TerminatedTreatmentCancers / Mucositis1
3TerminatedTreatmentCancers / Pain1
3TerminatedTreatmentFracture Bone / Pain, Acute / Trauma, Multiple1
3TerminatedTreatmentHeadaches1
3Unknown StatusNot AvailableInduction of Total Intravenous General Anesthesia1
3Unknown StatusSupportive CareCancers1
3Unknown StatusTreatmentDiabetic Neuropathies / Pain1
3Unknown StatusTreatmentObesity, Morbid1
3Unknown StatusTreatmentPost-Operative Pain1
3WithdrawnDiagnosticSuicidal Ideation / Suicide1
3WithdrawnPreventionPhantom Pain1
3WithdrawnTreatmentEpilepsies / Refractory seizure disorders1
3WithdrawnTreatmentMucositis1
4Active Not RecruitingOtherCardiac Diseases1
4Active Not RecruitingPreventionAnaesthesia therapy1
4Active Not RecruitingPreventionAnesthesia, Intratracheal / Hernia / Intravenous Anesthesia / Pain, Acute / Pain, Chronic1
4Active Not RecruitingPreventionArterial hypoxia / BMI >30 kg/m2 / Pain1
4Active Not RecruitingPreventionEndometrial Adenocarcinomas1
4Active Not RecruitingTreatmentAnaesthesia therapy1
4Active Not RecruitingTreatmentIdiopathic Scoliosis / Post-Operative Pain / Scoliosis1
4Active Not RecruitingTreatmentTrigeminal Neuralgia (TN)1
4CompletedNot AvailableFailed Moderate Sedation During Procedure1
4CompletedBasic ScienceHealthy Volunteers / Schizophrenic Disorders1
4CompletedBasic SciencePost-anesthesia Recovery1
4CompletedOtherDepression / Depression, Anxiety / Major Depressive Disorder (MDD)1
4CompletedOtherHeart Septal Defects, Atrial / Heart Valve Disease1
4CompletedPreventionAdenotonsillectomy1
4CompletedPreventionCesarean Delivery / Ketamine / Perinatal Depression / Postpartum Depression1
4CompletedPreventionChronic Pain, Postoperative1
4CompletedPreventionCoronary Artery Disease1
4CompletedPreventionEmergence Agitation1
4CompletedPreventionHemodynamics Instability / Renal Function Disorder1
4CompletedPreventionHypnotic / Specified Sedative1
4CompletedPreventionIdiopathic Scoliosis / Spondylolisthesis1
4CompletedPreventionOculocardiac Reflex / Premedication1
4CompletedPreventionPersistent Pain / Postoperative Hyperalgesia1
4CompletedPreventionPostoperative pain2
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedSupportive CareAnesthesia; Reaction1
4CompletedTreatmentAbscesses / Pain1
4CompletedTreatmentAirway Control / Anaesthesia therapy / Complications / Intubations1
4CompletedTreatmentAnaesthesia therapy1
4CompletedTreatmentAnalgesics / Pain, Chronic / Postoperative pain1
4CompletedTreatmentBariatric Surgery Candidate / Postoperative pain1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentCataracts / Phacoemulsification1
4CompletedTreatmentChild Behavior / Conscious Sedation Failure During Procedure / Dental Decay1
4CompletedTreatmentChild Behavior / Dental Decay1
4CompletedTreatmentColonoscopy / Sedation, Conscious1
4CompletedTreatmentConscious Sedation Failure During Procedure2
4CompletedTreatmentDeep Sedation / Delayed Emergence From Anesthesia1
4CompletedTreatmentDepression1
4CompletedTreatmentDepression, Bipolar / Unipolar Depression1
4CompletedTreatmentEfficacy and Safety of Mivacurium Chloride for Pediatric Patients1
4CompletedTreatmentElectroconvulsive Therapy / Major Depressive Disorder (MDD)1
4CompletedTreatmentEmergency Psychiatric / Psychiatric Disorders / Psychomotor Agitation / Tranquilizers1
4CompletedTreatmentHeadaches1
4CompletedTreatmentHealthy Controls1
4CompletedTreatmentHepatectomy1
4CompletedTreatmentIntubation; Difficult1
4CompletedTreatmentKetamine Induced Agitation1
4CompletedTreatmentMajor Depressive Disorder (MDD)1
4CompletedTreatmentMajor Depressive Disorder (MDD) / Suicidal Ideation1
4CompletedTreatmentMajor Depressive Episode1
4CompletedTreatmentModerate, Deep Sedation1
4CompletedTreatmentNeoplasms, Breast1
4CompletedTreatmentOpiate Dependence1
4CompletedTreatmentPain5
4CompletedTreatmentPain, Acute1
4CompletedTreatmentPain, Acute / Sickle Cell Crisis1
4CompletedTreatmentPain, Neuropathic1
4CompletedTreatmentPain / Pain, Acute1
4CompletedTreatmentPediatric Rigid Bronchoscopy1
4CompletedTreatmentPost Operative Pain1
4CompletedTreatmentPostoperative pain2
4CompletedTreatmentProcedural Sedation1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPsychoses, Substance-Induced1
4CompletedTreatmentRetinal Disorders1
4CompletedTreatmentSedation for Mechanical Ventilation1
4CompletedTreatmentSedation therapy1
4CompletedTreatmentShivering1
4CompletedTreatmentSuicidal Ideation1
4CompletedTreatmentTreatment Resistant Depression (TRD)1
4Enrolling by InvitationTreatmentAnterior Cervical Discectomy and Fusion (ACDF)1
4Enrolling by InvitationTreatmentDepressive Disorders1
4Not Yet RecruitingPreventionTourniquet Pain1
4Not Yet RecruitingSupportive CareBronchoscopy1
4Not Yet RecruitingTreatmentAnaesthesia therapy / Depression / Ketamine1
4Not Yet RecruitingTreatmentAnaesthesia therapy / Electroconvulsive Therapy1
4Not Yet RecruitingTreatmentChild, Only / Postoperative pain / Sleep Disorder; Breathing-Related1
4Not Yet RecruitingTreatmentIntensive Care / Pain Management / Pain, Intractable / Pressure Ulcers1
4Not Yet RecruitingTreatmentPain / Pain, Acute1
4Not Yet RecruitingTreatmentTreatment Resistant Depression (TRD)1
4RecruitingNot AvailableGeneral Surgery1
4RecruitingNot AvailablePostoperative pain1
4RecruitingBasic ScienceConsciousness / Loss of Consciousness1
4RecruitingDiagnosticAnesthesia Intubation Complications1
4RecruitingOtherOtolaryngeal Cancer1
4RecruitingPreventionAmnestic / Cognitive Disorders / Delirium / Dementias / Inflammatory Reaction1
4RecruitingPreventionAnaesthesia therapy / Chronic, severe Obstructive Pulmonary Disease / Lungcancer / Mild Chronic Obstructive Pulmonary Disease / Moderate Chronic Obstructive Pulmonary Disease1
4RecruitingPreventionGallbladder Inflammation1
4RecruitingPreventionPostoperative Delirium1
4RecruitingPreventionPostoperative pain1
4RecruitingPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting1
4RecruitingSupportive CareBariatrics / BMI >30 kg/m2 / Bypass, Gastric / Endoscopy / Sleep Apnea Syndromes1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingSupportive CareCongenital Heart Disease (CHD)1
4RecruitingSupportive CareHealthy Volunteers / Hemorrhage1
4RecruitingTreatmentAcute Kidney Injury (AKI) / Impaired Renal Function / Pharmacokinetics / Renal Failure1
4RecruitingTreatmentAnxiety Disorders / Major Depressive Disorder (MDD)1
4RecruitingTreatmentCardio-respiratory arrest / Respiratory Arrest1
4RecruitingTreatmentCaries of Infancy / Dental Anxiety1
4RecruitingTreatmentDepression2
4RecruitingTreatmentDepressive Disorder, Treatment-Resistant1
4RecruitingTreatmentFeeling Anxious / Pediatric ALL / Procedural anxiety1
4RecruitingTreatmentIntubation Complications1
4RecruitingTreatmentKetamine / Treatment Resistant Depression (TRD)1
4RecruitingTreatmentLaceration of Skin1
4RecruitingTreatmentLaminectomy1
4RecruitingTreatmentMajor Depressive Disorder (MDD)2
4RecruitingTreatmentMigraines1
4RecruitingTreatmentNon Elective Cesarean Section and Ketamine Analgesia1
4RecruitingTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
4RecruitingTreatmentPain3
4RecruitingTreatmentPain, Acute / Pain, Chronic / Pain, Neuropathic1
4RecruitingTreatmentPain, Chronic1
4RecruitingTreatmentPain / Postoperative Period1
4RecruitingTreatmentPostoperative pain1
4RecruitingTreatmentRib Fracture Multiple / Rib Fractures1
4RecruitingTreatmentRib Fractures / Wounds and Injuries1
4RecruitingTreatmentShock, Septic1
4RecruitingTreatmentMinor burns1
4SuspendedBasic SciencePain1
4TerminatedTreatmentAnaesthesia therapy1
4TerminatedTreatmentHeart Diseases1
4TerminatedTreatmentPain1
4TerminatedTreatmentPain, Acute / Posttraumatic Stress Disorders / Wound Care1
4TerminatedTreatmentPostoperative pain1
4TerminatedTreatmentSickle Cell Disorders1
4TerminatedTreatmentThoracic Surgery1
4Unknown StatusNot AvailableAnalgesia, Postoperative1
4Unknown StatusNot AvailablePost Operative Inflammatory Marker Levels1
4Unknown StatusPreventionHyperalgesia / Illness, Chronic / Pain / Pain, Neuropathic1
4Unknown StatusTreatmentAcute Abdomen / Acute Low Back Pain / Extremity Pain, Acute / Flank Pain, Acute / Other Acute Pain1
4Unknown StatusTreatmentCancer, Breast / Pain1
4Unknown StatusTreatmentChronic Low Back Pain (CLBP)1
4Unknown StatusTreatmentCoronary Artery Bypass Surgery1
4Unknown StatusTreatmentDepressive Disorders1
4Unknown StatusTreatmentDepressive Symptoms / Electroconvulsive Therapy / Impaired Cognition1
4Unknown StatusTreatmentLaceration1
4Unknown StatusTreatmentLacertaions1
4Unknown StatusTreatmentPostoperative pain2
4Unknown StatusTreatmentSternotomy1
4WithdrawnTreatmentAcute Agitation1
4WithdrawnTreatmentAlcohol Withdrawal Syndrome(AWS)1
4WithdrawnTreatmentAnaesthesia therapy / General Surgery / Pain1
4WithdrawnTreatmentDepression / Suicidal Ideation / Suicide1
4WithdrawnTreatmentFeeling Anxious / Pain / Thermal Hyperalgesia1
4WithdrawnTreatmentPain, Acute / Postoperative pain / Surgery, Colorectal1
4WithdrawnTreatmentTreatment Resistant Depression (TRD)1
Not AvailableActive Not RecruitingSupportive CareIntra-operative Anesthesia2
Not AvailableActive Not RecruitingSupportive CareIntra-operative Anesthesia and Analgesia Effects1
Not AvailableActive Not RecruitingTreatmentBMI >30 kg/m21
Not AvailableActive Not RecruitingTreatmentDepressive Disorder, Treatment-Resistant1
Not AvailableCompletedNot AvailableAcute Gouty Arthritis / Arthritis / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableCompletedNot AvailableColonoscopy / Fentanyl / Ketamine1
Not AvailableCompletedNot AvailableEndoscopy1
Not AvailableCompletedNot AvailableIntubating Conditions1
Not AvailableCompletedNot AvailableMajor Depressive Disorder (MDD) / Post-Traumatic Stress Disorder (PTSD)1
Not AvailableCompletedNot AvailablePain, Chronic1
Not AvailableCompletedNot AvailableRhytidoplasty1
Not AvailableCompletedBasic ScienceAbnormal Vascular Flow / Healthy Volunteers1
Not AvailableCompletedBasic ScienceFunctional Neuroimaging1
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedBasic ScienceThe Pk of IV Ketamine in Children With Heart Disease1
Not AvailableCompletedDiagnosticAnaesthesia therapy / Pain1
Not AvailableCompletedHealth Services ResearchAlcoholism1
Not AvailableCompletedHealth Services ResearchChronic Cough (CC)1
Not AvailableCompletedHealth Services ResearchHyperalgesia / Pain / Pain, Chronic1
Not AvailableCompletedOtherHealthy Volunteers1
Not AvailableCompletedOtherPain1
Not AvailableCompletedPreventionAcute Respiratory Failure / Reduction in Opiate Use1
Not AvailableCompletedPreventionAlveolar Hypoventilation1
Not AvailableCompletedPreventionBlood Pressures1
Not AvailableCompletedPreventionChronic Post-thoracotomy Pain1
Not AvailableCompletedPreventionPostoperative pain1
Not AvailableCompletedPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableCompletedPreventionPsychomotor Agitation1
Not AvailableCompletedPreventionQt Interval, Variation in1
Not AvailableCompletedSupportive CareAbscesses / Fracture Bone1
Not AvailableCompletedSupportive CareAdult Patients Undergoing ERCP1
Not AvailableCompletedSupportive CareC.Surgical Procedure; Cardiac1
Not AvailableCompletedTreatmentAbscesses / Anaesthesia therapy / Analgesia / Fracture Bone / Joint dislocations1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentAnal Condyloma / Fissure in Ano / Hemorrhoids / Rectal Fistulas1
Not AvailableCompletedTreatmentChronic Low Back Pain (CLBP)1
Not AvailableCompletedTreatmentComplication of Labor and/or Delivery / Effects of; Anesthesia, Spinal and Epidural, in Pregnancy / Ketamine Adverse Reaction1
Not AvailableCompletedTreatmentDepression1
Not AvailableCompletedTreatmentDepression / Suicidal Ideation1
Not AvailableCompletedTreatmentDepression / Suicide Ideation1
Not AvailableCompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
Not AvailableCompletedTreatmentHeadaches1
Not AvailableCompletedTreatmentHepatectomy1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)4
Not AvailableCompletedTreatmentOrientation / Post-anesthesia Recovery1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentPost Operative Pain1
Not AvailableCompletedTreatmentPost Thoracotomy Pain1
Not AvailableCompletedTreatmentPostoperative Pain Management1
Not AvailableCompletedTreatmentPostoperative pain3
Not AvailableNot Yet RecruitingNot AvailableAnaesthesia therapy / Pain1
Not AvailableNot Yet RecruitingNot AvailableHealthy Volunteers1
Not AvailableNot Yet RecruitingBasic ScienceSedation therapy1
Not AvailableNot Yet RecruitingOtherDepression in Old Age / Ketamine1
Not AvailableNot Yet RecruitingPreventionAnalgesia, Postoperative1
Not AvailableNot Yet RecruitingTreatmentBrachial Plexus Block / Shoulder Dislocation1
Not AvailableNot Yet RecruitingTreatmentMajor Depressive Disorder (MDD)1
Not AvailableNot Yet RecruitingTreatmentPain1
Not AvailableNot Yet RecruitingTreatmentPain, Acute1
Not AvailableNot Yet RecruitingTreatmentSedation therapy1
Not AvailableNot Yet RecruitingTreatmentSuicide1
Not AvailableNot Yet RecruitingTreatmentSurgery, Cardiac1
Not AvailableRecruitingNot AvailableBMI >30 kg/m2 / Laparoscopic Gastric Bypass / Postoperative pain1
Not AvailableRecruitingNot AvailableStress Disorders, Post-Traumatic1
Not AvailableRecruitingBasic ScienceAmnesia / Anaesthesia therapy / Anesthetics / Pain / Sedation, Conscious1
Not AvailableRecruitingBasic ScienceCognitive Disorders / Delirium / Depression / Seizures1
Not AvailableRecruitingBasic ScienceHealthy Volunteers1
Not AvailableRecruitingBasic ScienceMajor Depressive Disorder (MDD) / Post-Traumatic Stress Disorder (PTSD)1
Not AvailableRecruitingDiagnosticNeurocostal neuralgia1
Not AvailableRecruitingHealth Services ResearchOpioid Free Anaesthesia1
Not AvailableRecruitingHealth Services ResearchSedation therapy1
Not AvailableRecruitingOtherColorectal Cancers1
Not AvailableRecruitingPreventionAcute Kidney Injury (AKI) / Cognitive Disorders / Delirium1
Not AvailableRecruitingPreventionOpioids Use / Postoperative pain1
Not AvailableRecruitingTreatmentAnaesthesia therapy / General Surgery / Pain1
Not AvailableRecruitingTreatmentFracture Bone / Pain, Acute1
Not AvailableRecruitingTreatmentKetamine Adverse Reaction / Postoperative pain1
Not AvailableRecruitingTreatmentKetamine; Depression Symptom; Brain Tumor; Outcome / Ketamine; Depressive Symptom; Neurosurgery; Perioperative Period1
Not AvailableRecruitingTreatmentMajor Depressive Disorder (MDD)1
Not AvailableRecruitingTreatmentMajor Depressive Disorder (MDD) / Severe Depression / Treatment Resistant Depression (TRD)1
Not AvailableRecruitingTreatmentPTSD1
Not AvailableRecruitingTreatmentSickle Cell Disorders1
Not AvailableSuspendedTreatmentPaediatric Flexible Bronchoscopy1
Not AvailableTerminatedBasic ScienceChanges in Brain Network Connectivity1
Not AvailableTerminatedOtherDepression1
Not AvailableTerminatedPreventionPain1
Not AvailableTerminatedTreatmentDepression, Bipolar / Major Depressive Disorder (MDD)1
Not AvailableTerminatedTreatmentDepression / Major Depressive Disorder (MDD)1
Not AvailableTerminatedTreatmentHysterectomy1
Not AvailableTerminatedTreatmentNausea / Pain1
Not AvailableTerminatedTreatmentPain / Sickle Cell Disorders1
Not AvailableTerminatedTreatmentProcedural Sedation / Procedural Sedation and Analgesia1
Not AvailableTerminatedTreatmentSedation therapy1
Not AvailableTerminatedTreatmentThoracotomy1
Not AvailableUnknown StatusNot AvailableChildren Requiring Sedation for MRI/CT1
Not AvailableUnknown StatusPreventionKnee Osteoarthritis (Knee OA) / Necrosis of Femoral Head1
Not AvailableUnknown StatusPreventionPain1
Not AvailableUnknown StatusPreventionPain, Acute / Pain, Chronic / Thyroid1
Not AvailableUnknown StatusSupportive CareVirtual Reality Therapy1
Not AvailableUnknown StatusTreatmentCancers / Pain / Tolerance1
Not AvailableUnknown StatusTreatmentChronic Lung Diseases1
Not AvailableUnknown StatusTreatmentHyperalgesia / Post Operative Pain1
Not AvailableUnknown StatusTreatmentPain, Acute1
Not AvailableUnknown StatusTreatmentPain / Psychomotor Agitation / Respiratory Insufficiency1
Not AvailableWithdrawnNot AvailablePain1
Not AvailableWithdrawnPreventionHypercarbia1
Not AvailableWithdrawnSupportive CarePain / Traumas1
Not AvailableWithdrawnTreatmentDepression1
Not AvailableWithdrawnTreatmentMajor Depressive Disorder (MDD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bioniche Pharma
  • Hospira Inc.
  • JHP Pharmaceuticals LLC
  • Medisca Inc.
  • Monarch Pharmacy
  • Pharmedium
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
InjectionIntramuscular; Intravenous10 mg/1mL
InjectionIntramuscular; Intravenous100 mg/1mL
InjectionIntramuscular; Intravenous50 mg/1mL
SolutionIntramuscular; Intravenous50 mg
Injection, solutionIntramuscular; Intravenous10 mg/1mL
Injection, solutionIntramuscular; Intravenous100 mg/1mL
Injection, solutionIntramuscular; Intravenous50 mg/1mL
Injection, solution, concentrateIntramuscular; Intravenous100 mg/1mL
Injection, solution, concentrateIntramuscular; Intravenous50 mg/1mL
SolutionIntramuscular; Intravenous10 mg
SolutionIntramuscular; Intravenous100 mg
SolutionIntramuscular; Intravenous500 mg
CreamTopical
Prices
Unit descriptionCostUnit
Ketamine hcl powder7.22USD g
Ketamine hcl-ns 50 mg/5 ml syr2.82USD ml
Ketamine 100 mg/ml vial2.36USD ml
Ketalar 100 mg/ml vial1.95USD ml
Ketamine hcl-ns 100 mg/10 ml1.95USD ml
Ketamine HCl 50 mg/ml Solution1.77USD ml
Ketalar 10 mg/ml vial0.99USD ml
Ketamine 10 mg/ml vial0.99USD ml
Ketalar 50 mg/ml vial0.75USD ml
Ketamine 50 mg/ml vial0.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)92.5ºCMedical toxicology of drug abuse. (2012)
water solubilitySoluble'MSDS'
logP3.120Medical toxicology of drug abuse. (2012)
pKa7.5Ketamine monograph
Predicted Properties
PropertyValueSource
Water Solubility0.0464 mg/mLALOGPS
logP2.69ALOGPS
logP3.35ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)18.78ChemAxon
pKa (Strongest Basic)7.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.1 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity65.55 m3·mol-1ChemAxon
Polarizability24.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9826
Caco-2 permeable+0.6326
P-glycoprotein substrateSubstrate0.5753
P-glycoprotein inhibitor INon-inhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6737
CYP450 2C9 substrateNon-substrate0.6363
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.7323
CYP450 2C9 inhibitorNon-inhibitor0.7985
CYP450 2D6 inhibitorNon-inhibitor0.6912
CYP450 2C19 inhibitorNon-inhibitor0.5347
CYP450 3A4 inhibitorNon-inhibitor0.8253
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5426
Ames testNon AMES toxic0.7223
CarcinogenicityNon-carcinogens0.8878
BiodegradationNot ready biodegradable0.9937
Rat acute toxicity2.3939 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8859
hERG inhibition (predictor II)Inhibitor0.6047
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0930000000-8216e02922628a5070cf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-7704dbbfa717abc4bab2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-aff2b684d97275321043
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0290000000-1707dec51cc3e89964c9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0940000000-59871faec16835eb1b3a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-ca62e82b4a1dfb81b3b0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-6c243d7b1c2e8cf69efa
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-441a423105753e2c8b9c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-24585e7c2431b3b9319e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0290000000-c9d734b085ec94dabd9a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0940000000-054d77385726d4e35e20
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-8c263bb521fb6ebe6cac
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-702873d66ce0d419711d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0900000000-e23ba411aa96df9b5d6f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0090000000-5f14196db213c95f3e71
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000i-0090000000-85385cf96aa2ac05921a
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-05br-0390000000-9177663a5915fac51aa7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-0910000000-d00d242dae695dc5aff9
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-0900000000-95c2a8805f1587266fea
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-004i-1900000000-9e61adc80771178de9d3
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-00di-0190000000-686c139c454aea662d84

Taxonomy

Description
This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Chlorobenzenes
Alternative Parents
Aralkylamines / Aryl chlorides / Cyclic ketones / Dialkylamines / Organopnictogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives
Substituents
Chlorobenzene / Aralkylamine / Aryl chloride / Aryl halide / Ketone / Cyclic ketone / Secondary aliphatic amine / Secondary amine / Amine / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary amino compound, monochlorobenzenes, cyclohexanones (CHEBI:6121)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Smothers CT, Woodward JJ: Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. J Pharmacol Exp Ther. 2007 Aug;322(2):739-48. Epub 2007 May 14. [PubMed:17502428]
  2. Harrison NL, Simmonds MA: Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985 Feb;84(2):381-91. [PubMed:2858237]
  3. Sinner B, Graf BM: Ketamine. Handb Exp Pharmacol. 2008;(182):313-33. doi: 10.1007/978-3-540-74806-9_15. [PubMed:18175098]
  4. Radovanovic D, Pjevic M: [Ketamine: the past 30 years and its future]. Med Pregl. 2003 Sep-Oct;56(9-10):439-45. [PubMed:14740534]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Tachykinin receptor activity
Specific Function
This is a receptor for the tachykinin neuropeptide substance P. It is probably associated with G proteins that activate a phosphatidylinositol-calcium second messenger system. The rank order of aff...
Gene Name
TACR1
Uniprot ID
P25103
Uniprot Name
Substance-P receptor
Molecular Weight
46250.5 Da
References
  1. Okamoto T, Minami K, Uezono Y, Ogata J, Shiraishi M, Shigematsu A, Ueta Y: The inhibitory effects of ketamine and pentobarbital on substance p receptors expressed in Xenopus oocytes. Anesth Analg. 2003 Jul;97(1):104-10, table of contents. [PubMed:12818951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
Partial agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Seeman P, Guan HC, Hirbec H: Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse. 2009 Aug;63(8):698-704. doi: 10.1002/syn.20647. [PubMed:19391150]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Salt PJ, Barnes PK, Beswick FJ: Inhibition of neuronal and extraneuronal uptake of noradrenaline by ketamine in the isolated perfused rat heart. Br J Anaesth. 1979 Sep;51(9):835-8. [PubMed:508488]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synt...
Gene Name
OPRK1
Uniprot ID
P41145
Uniprot Name
Kappa-type opioid receptor
Molecular Weight
42644.665 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Smith DJ, Pekoe GM, Martin LL, Coalgate B: The interaction of ketamine with the opiate receptor. Life Sci. 1980 Mar 10;26(10):789-95. [PubMed:6246318]
  2. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...

Components:
References
  1. Hustveit O, Maurset A, Oye I: Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol. 1995 Dec;77(6):355-9. [PubMed:8835358]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...

Components:
References
  1. Martin LL, Bouchal RL, Smith DJ: Ketamine inhibits serotonin uptake in vivo. Neuropharmacology. 1982 Feb;21(2):113-8. [PubMed:6460944]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Martin LL, Bouchal RL, Smith DJ: Ketamine inhibits serotonin uptake in vivo. Neuropharmacology. 1982 Feb;21(2):113-8. [PubMed:6460944]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Appadu BL, Lambert DG: Interaction of i.v. anaesthetic agents with 5-HT3 receptors. Br J Anaesth. 1996 Feb;76(2):271-3. [PubMed:8777109]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Not Available
Specific Function
Not Available
Gene Name
CHRNA7
Uniprot ID
Q693P7
Uniprot Name
Alpha-7 nicotinic cholinergic receptor subunit
Molecular Weight
2987.635 Da
References
  1. Kohrs R, Durieux ME: Ketamine: teaching an old drug new tricks. Anesth Analg. 1998 Nov;87(5):1186-93. [PubMed:9806706]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Kohrs R, Durieux ME: Ketamine: teaching an old drug new tricks. Anesth Analg. 1998 Nov;87(5):1186-93. [PubMed:9806706]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tetrahydrobiopterin binding
Specific Function
Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter. P...
Gene Name
NOS1
Uniprot ID
P29475
Uniprot Name
Nitric oxide synthase, brain
Molecular Weight
160969.095 Da
References
  1. Kohrs R, Durieux ME: Ketamine: teaching an old drug new tricks. Anesth Analg. 1998 Nov;87(5):1186-93. [PubMed:9806706]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:53